Improving lives
through innovation
Nyrada Inc (ASX:NYR)
ABRN 625 401 818
Annual report
For the year ended 30 June 2022
NYRADA INC (ASX:NYR)
Nyrada Overview
Nyrada is developing novel, high value small molecule drugs:
Drug Candidate
Indication
Aim
Target Market
NYX-PCSK9i
Oral PCSK9 inhibitor
Cholesterol-Lowering
NYR-BI02
TRPC 3/6/7 blocker
Brain Injury
Best-in-class small molecule drug to
disrupt and broaden the class in
cardiovascular management, offering
the convenience of a pill
First-in-class treatment to prevent
secondary brain injury and reduce
disability following moderate-severe
TBI, concussion, or stroke
>18M patients (US)1
~5.5M patients/ year
(globally)2
Key drivers of future value
New patents
secured to
expand IP
protection
Brain Injury
Program
Phase I Study
confirms
safety
Efficacy signal
in joint
Nyrada/
WRAIR/ UNSW
TBI Study
Safety
confirmed in
Phase I
Cholesterol-
Lowering
Study
Key milestones in the next 18 months
Results of
preclinical stroke
model study
Cholesterol-
Lowering Program
preclinical safety,
pharmacology
and toxicology
studies
Brain-Injury
Program
preclinical safety,
pharmacology,
and toxicology
studies
Commencement
of Cholesterol-
Lowering Phase I
Study
Commencement
of Brain-Injury
Phase I Study
TBI efficacy study
with Walter Reed
Army Institute of
Research and
UNSW Sydney
2
ANNUAL REPORT FY22
Corporate Directory
Board of Directors
John Moore
Peter Marks (resigned 1 August 2022)
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
Gisela Mautner (appointed 1 August 2022)
Company Secretary
David Franks
Registered office in Australia and
principal place of business
Registered office in place
of incorporation
Suite 2, Level 3
828 Pacific Highway
Gordon, NSW 2072
Australia
Tel: +61 2 9498 3390
1209 Orange Street
Wilmington, Delaware 19801
United States of America
Share/CDI Registry
Automic Pty Ltd
Level 5, 126 Phillip Street
Sydney, NSW 2000
Australia
Auditor
William Buck Audit (Vic) Pty Ltd
Level 20, 181 William Street
Melbourne, VIC 3000
Australia
Stock exchange listing
Nyrada Inc. instruments registered for trade on the Australian Securities
Exchange are CHESS Depositary Interests (CDIs).
One CDI is equivalent to one Share, being Class A Common Stock.
ASX Code
Website
Email
NYR
www.nyrada.com
info@nyrada.com
3
NYRADA INC (ASX:NYR)
Contents
Chairman’s Letter
CEO Report
Directors’ Report
Auditor’s Independence Declaration
Independent Auditor’s Report
Consolidated Statement of Profit or Loss and Other Comprehensive Income
Consolidated Statement of Financial Position
Consolidated Statement of Changes in Equity
Consolidated Statement of Cash Flows
Notes to the Financial Statements
Directors’ Declaration
Shareholder Information
References
5
8
12
33
34
38
39
40
41
42
57
58
61
4
Chairman’s Letter
ANNUAL REPORT FY22
Dear Fellow Shareholders,
I am pleased to present Nyrada’s Annual Report for the financial year ended 30 June
2022, during which we saw notable progress in both of our drug development programs.
Our vision is to improve lives and offer hope through innovation. This is reflected in the
objectives of both our Cholesterol-Lowering and Brain Injury drug development
programs, which target diseases with substantial market size and unmet patient need.
The team has invested significant effort over the year as Nyrada evolves from a
preclinical drug discovery company to a pharmaceutical company approaching the
clinic. We are currently focused on completing the required preclinical studies before
entering first-in-human trials.
Considerable progress was made in both our programs. In addition to lowering
cholesterol levels in a mouse model of hyperlipidemia, a candidate from Nyrada’s
PCSK9 inhibitor family of compounds was shown to attenuate the early stages of
atherosclerosis in a novel human tissue-engineered blood vessel model of the disease,
developed by researchers at Duke University. Our oral drug candidate has the potential
to provide a valuable alternative to expensive and inconvenient injectable PCSK9
inhibitor drugs.
Nyrada is also developing a first-in-class neuroprotectant drug to prevent secondary
brain injury. This is the injury that occurs in the hours and days following the primary
injury, leading to increased disability and reduced quality of life. Each year, globally,
more than 60 million people suffer a concussion or moderate to severe traumatic brain
injury (TBI)3, yet no FDA-approved treatment for secondary brain injury exists. For stroke
the need is similar, with only limited treatment options available. Nyrada’s NYR-BI02 drug
candidate offers the potential to reduce the secondary injury, and therefore reduce
patient mortality and disability and improve quality of life.
Recently, the team revealed NYR-BI02 targets three Transient Receptor Potential
Canonical (TRPC) ion channel subtypes, making it a versatile, potent blocker of the
channel. This creates significant potential for future studies in a range of other
neurological diseases, along with diseases of the kidneys, heart, lung, and muscle.
As part of our existing collaboration with the Walter Reed Army Institute of Research,
Nyrada will initially test the efficacy of its NYR-BI02 molecule as a TRPC 3/6/7 channel
blocker in a model of TBI. The efficacy study will also involve injury volume assessments
using a specialised MRI technique developed at UNSW Sydney.
The last twelve months have been a challenging period for global equity markets, as
central banks continue to lift interest rates to slow rising inflation amidst ongoing
economic uncertainty, impacting investor sentiment across a variety of sectors,
including biotech, life sciences and healthcare.
Our key focus remains on creating value for our shareholders. We have actively taken
steps during the year to raise awareness of our technologies with investors and
potential partners via our participation in industry and investment conferences, helped
by the easing of COVID-related travel restrictions.
“High LDL-cholesterol is a significant risk factor for cardiovascular disease and is
most prevalent in older adults. The World Health Organization estimates that by
2030, 1 in 6 people will be aged 60 years or over, accounting for ~1.4 billion people
globally. A large study found that of an estimated 27 million US adults taking statins,
70% were not able to reach a safe target cholesterol level. Nyrada’s oral PCSK9
inhibitor drug has the potential to be a next generation alternative to expensive and
inconvenient PCSK9 injectable drugs.”
5
NYRADA INC (ASX:NYR)
Nyrada is fortunate to be in a strong position with respect to broader supply chain and
inflationary pressures. In part, this is due to pre-arranged pricing secured for preclinical studies,
as well as proactive measures taken by the Company to hedge our exposure to the US Dollar.
The ongoing global impacts of COVID-19 have, however, had a modest impact on our drug
manufacture and timelines. As a result, the anticipated Phase I first-in-human studies for the
Cholesterol-Lowering program are now expected to commence in the first half of CY2023.
As Nyrada evolves, so too do the skills and expertise requirements of our Board. In recognition
of the importance of adding skills that align with our growth strategy as we progress to clinical
development, we were delighted to welcome Dr. Gisela Mautner as Non-Executive Director.
Gisela brings more than 20 years of extensive leadership experience in global pharmaceutical
organisations across multiple therapeutic areas. Her experience overseeing drug development
at some of the world’s leading pharmaceutical companies will be invaluable as Nyrada’s
programs advance towards the clinic.
Peter Marks also retired from the Board after supporting the Company through its IPO and first
years as a public company. I would like to extend the Board’s thanks to Mr Marks for his valuable
contribution to Nyrada during his term as Non-Executive Director. His deep capital markets
knowledge and networks have been invaluable in supporting the early growth of the Company.
We remain confident in our strategy and in the long-term potential of both drug programs.
Indeed, the markets for Cholesterol-Lowering and Brain Injury are growing due to the increasing
incidence, as well as expanding awareness of the need for better treatment options. Nyrada’s
small molecule drugs present significant treatment advantages that differentiate them from
existing options currently available in the market.
I wish to acknowledge the ongoing support of our Scientific Advisory Board, which has a strong
track record in finding and realising the value of biotech companies. Their counsel and input
have been integral to the success of our programs to date.
On behalf of the Board, I’d also like to thank our shareholders for their support of Nyrada and
extend our gratitude to the operational team for their perseverance throughout the year. Our
highly dedicated management team continues to lead Nyrada from strength to strength,
working hard to advance our programs to the clinic.
Looking ahead, Nyrada is entering an exciting phase as it approaches first-in-human trials for
both of its programs, and we are optimistic of the path ahead. We look forward to keeping you
updated on progress over the next year.
Yours sincerely,
John Moore
Non-Executive Chairman
Nyrada Inc.
6
“Globally, we continue to see growing interest in the
development of oral PCSK9 inhibitors, which clinicians
consider to be an optimal approach to LDL-cholesterol
lowering as an adjunct to statin treatment.”
NYRADA INC (ASX:NYR)
CEO Report
Dear Fellow Shareholders,
I am pleased to share our results and operating review for FY2022.
The major operational challenge during the past 12 months has been the COVID-19
pandemic which has continued to disrupt global supply chains and logistics. While
Nyrada’s drug manufacturing timelines were temporarily impacted by COVID-related
lockdowns in Shanghai, China, delays were minimised because of the exceptional
efforts of employees at the Contract Manufacturing Organisation (CMO) engaged by
Nyrada, who worked
lockdown.
Notwithstanding, we have continued to deliver promising preclinical results in both our
Cholesterol-Lowering and Brain Injury Programs.
lost during
tirelessly
recover
time
the
to
In the Cholesterol-Lowering program, exploratory analysis conducted as part of a
successful in vivo cholesterol efficacy study of drug candidate NYX-PCSK9i, delivered
encouraging results that further support its mechanism of action in lowering cholesterol.
Furthermore, in a novel human tissue-engineered model of atherosclerosis developed
by researchers at Duke University, an optimised analogue of NYX-PCSK9i was shown to
block the early phases of atherosclerosis, which is the chronic inflammatory response
to elevated LDL-cholesterol leading to a build-up of plaque in the inner lining of the
arteries. This analogue also exhibited superior pharmacokinetic parameters (improved
absorption and distribution) in the study and accordingly, will be evaluated in Nyrada’s
Phase I study in the first half of CY2023.
The results of the atherosclerotic study are an exciting development in understanding
lowering LDL-cholesterol,
the broader applications for PCSK9
particularly as atherosclerotic plaque build-up is a major cause of cardiovascular
disease. Additionally, there continues to be encouraging industry interest globally in the
development of oral PCSK9 inhibitors, which clinicians consider to be an optimal
approach to LDL-cholesterol lowering as an adjunct to statin treatment.
inhibitors beyond
Moreover, Nyrada’s lead brain injury drug candidate, NYR-BI02, a TRPC channel blocker,
showed excellent oral bioavailability in an exploratory study, demonstrating it could
potentially be administered as an oral treatment for concussion, in addition to
intravenous dosing for severe traumatic brain injury (TBI) and stroke. The convenience
of an oral dose form that can be administered in the field immediately after a
concussion injury, without having to wait for hospitalisation, has the potential to
significantly improve patient recovery outcomes. Given the significant interest in this
area, these results open the door for the Company to potentially develop NYR-BI02 as
an oral treatment for concussion as an additional program.
Collectively, these results speak to the quality of the assets that the Nyrada team is
developing, and their potential to positively impact patient lives as both programs
advance towards the clinic.
We are also encouraged by recent published preclinical research that highlights
emerging opportunities in chronic heart and kidney disease indications for an orally
bioavailable drug targeting TRPC 3/6/7 channels. Nyrada
is reviewing these
opportunities and considering next steps.
“With the incidence of TBI increasing globally, this remains a large market with a
significant unmet clinical need. Through our relationships with the world-class
leading research teams at the Walter Reed Army Institute of Research (WRAIR) and
UNSW Sydney (UNSW), Nyrada is in a unique position to develop the first drug to
treat both TBI and stroke, with the potential to make a tangible difference in the
quality of life of people affected by these injuries.”
8
ANNUAL REPORT FY22
Cholesterol-Lowering Program
The World Health Organization (WHO) estimates that by 2030, 1 in 6 people will be aged 60 years
or over, accounting for ~1.4 billion people globally.4 High cholesterol, specifically LDL or “bad”
cholesterol, is a known significant risk factor for developing cardiovascular disease and is most
prevalent between the ages of 55-64 in Australia, and 40-59 in the US.5 A large US study6
estimated that more than 62 million Americans have risk factors associated with
cardiovascular disease, and are therefore eligible for cholesterol-lowering treatment. From this
population, approximately 27 million take a statin drug, the current first line treatment for high
LDL-cholesterol. Of those taking a statin, more than 18 million, or close to 70% are unable to
achieve their safe target cholesterol level. As the world’s population continues to age, patient
need for new, more effective, and convenient cholesterol-lowering drugs will only increase.
We have shown through preclinical studies that Nyrada’s small molecule PCSK9 inhibitor is able
to significantly lower LDL-cholesterol levels, while also increasing the number of LDL receptors
which are responsible for removing cholesterol from the bloodstream. The drug Nyrada is
developing is intended to be taken as a once-per-day pill, alone or in combination with a statin,
overcoming the inconvenience of expensive injectable PCSK9 inhibitors. Small molecule drugs
also have a lower manufacturing cost than biologics, which includes PCSK9 inhibitors.
The program is entering an exciting period as safety, pharmacology, and toxicology studies get
underway in the second half of this year, ahead of a Phase I first-in-human study expected to
commence in the first half of next year, to be run in Australia. The primary objective of the Phase
I study is to evaluate Nyrada’s drug candidate for safety and tolerability. However, a secondary
endpoint will assess blood cholesterol levels in cohorts treated for 14 days with Nyrada’s drug
candidate as a preliminary indication of the drug’s efficacy in humans.
I am delighted that Nyrada’s intellectual property portfolio also continues to grow with the
granting of patents for our PCSK9 inhibitor compounds in the US and Europe, providing
composition of matter protection through to 2038.
Brain Injury Program
Nyrada’s Brain Injury Program made significant progress during the year. We revealed the
biological target for the program as a class of proteins known as the “Canonical” Transient
Receptor Potential, or TRPC ion channels. After a brain injury, these channels remain “open”,
allowing calcium to accumulate in neuronal cells to toxic levels, leading to cell death.7 Nyrada’s
brain injury drug candidate, NYR-BI02, is a potent blocker of three subtypes of the TRPC channel
– TRPC 3/6/7, which are widely expressed in the brain. By targeting these channels, our brain
injury drug candidate can inhibit the entry of calcium into cells and thereby reduce secondary
brain injury. NYR-BI02 also readily crosses the intact blood-brain-barrier, indicating it can reach
therapeutic levels in an injured brain.
There is still no FDA-approved drug to treat TBI and only limited treatment options for stroke. To
the Company’s knowledge, there is also no other small molecule brain injury drug in
development that targets TRPC ion channels.
A recent report8 estimated that annually, ~55.9 million people globally experience a mild TBI,
with 5.48 million experiencing a severe TBI. More than 55 million people, or 0.7% of the world’s
population are thought to be living with the effects of medically treated TBI.
In the US, 4.8 million people are evaluated in emergency departments for TBI each year, with
total emergency department visits,
TBI being diagnosed
hospitalisations, and deaths.9 This is not just a civilian issue, with 1 in 5 US military service
members reporting experiencing a TBI during active duty.
in approximately 2% of
With the incidence of TBI increasing globally, this remains a large market with a significant
unmet clinical need. Through our relationships with the world-class leading research teams at
the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney (UNSW), Nyrada is in a
unique position to develop the first drug to treat both TBI and stroke, with the potential to make
a tangible difference in the quality of life of people affected by these injuries.
9
NYRADA INC (ASX:NYR)
As part of its active intellectual property protection program, Nyrada has filed a provisional patent
covering a library of molecules, including NYR-BI02, that block these TRPC channels. It is anticipated
that the patent will have coverage in the US, Australia, and Europe.
Outside of our collaboration with WRAIR, we are also evaluating the efficacy of our brain injury drug
candidate in a well-established preclinical stroke model, the Photothrombotic Model of Ischemia,
with results expected in the fourth quarter. This model was previously used by Nyrada to test the
efficacy of its first-generation molecule, which showed a promising efficacy signal.
Nyrada will initially test the efficacy of its NYR-BI02 molecule as a TRPC 3/6/7 channel blocker in a
model of TBI via our existing collaboration with WRAIR. The efficacy study will use the penetrating
traumatic brain injury (PTBI) model which has been developed by the WRAIR team to emulate
penetrating head wounds on the battlefield.
The complex nature of this study requires WRAIR to contribute considerable resources to enable its
completion. Like many large research organisations globally, the ongoing COVID-19 pandemic has
had an impact on some project timelines. The progression of this study is largely driven by
availability of the necessary resources at WRAIR, and we expect this study to commence in the new
year. Delays to the start of the TBI efficacy study will not impact the commencement of the Phase
I first-in-human study as these studies can be run at the same time.
The required safety, pharmacology and toxicology studies that will evaluate the safety and
tolerability of Nyrada’s lead brain injury drug candidate remain on track to commence during the
current quarter. With drug manufacture now complete, formulation development work is in
progress to ensure a suitable dose form for intravenous administration. This will not affect the
in vitro safety and toxicology studies but is necessary for the start of the in-vivo safety and
toxicology studies. While continued pressure on the availability of GLP study slots at CROs due to
the limited resources available during COVID-19 has made booking study slots difficult, we are in
regular dialogue with the CROs to ensure these studies are progressed expeditiously. Data from
these studies will determine the safe starting dose for the Phase I first-in-human study which is
now expected to start in the first half of CY2023. The Phase I study will be run in Australia and will
evaluate the safety and tolerability of NYR-BI02.
The Phase I study will support the development of Nyrada’s drug in both TBI and stroke indications,
significantly expanding the commercial opportunities potentially available to the Company.
I am proud of what Nyrada has achieved this year. Our success is testament to the significant time
and effort invested by our talented team. Nyrada’s transition to a clinical drug development
company over the coming 6-12 months is a turning point. The team and I wish to thank you for your
ongoing support and look forward to sharing news of our progress as the preclinical studies unfold
and our programs advance towards the clinic.
Yours Sincerely,
James Bonnar
CEO
Nyrada Inc
10
“Each year, globally, more than 60 million people suffer a
concussion or moderate to severe traumatic brain injury (TBI),
yet no FDA-approved treatment for secondary brain injury exists.
For stroke the need is similar, with only limited treatment options
available. Nyrada’s NYR-BI02 drug candidate offers the potential
to reduce the secondary injury, and therefore reduce patient
mortality and disability and improve quality of life. ”
NYRADA INC (ASX:NYR)
Directors’ Report
The Directors present their report, together with the financial statements, on the Consolidated Entity (referred to hereafter
as the 'Consolidated Entity') consisting of Nyrada Inc. (referred to hereafter as the 'Company' or 'Parent entity') and the
entities it controlled at the end of, or during, the year ended 30 June 2022.
Directors
The following persons were directors of Nyrada Inc. during the whole of the financial year and up to the date of this report,
unless otherwise stated:
John Moore
Peter Marks
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
Gisela Mautner
Non-Executive Chairman
Non-Executive Director (resigned 1 August 2022)
Non-Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director (appointed 1 August 2022)
John Moore
Non-Executive Chairman, joined the Board in June 2019
John Moore currently serves as Chairman of Trialogics, a clinical trial informatics business,
Chairman of Scientific Industries (SCND-OTCQB), a producer of laboratory instruments for
the life sciences industry and Chairman of Cormetech, a manufacturer of environmental
catalysts. John was CEO of Acorn Energy from 2006 to 2015, during which time the CoaLogix
business was acquired for US$11 million and sold for US$101 million, and the Comverge
business listed in the US before its sale to Constellation Energy. In 2002 he was a Partner and
CEO of Edson Moore Healthcare Ventures and acquired for US$148 million a portfolio of
sixteen drug delivery investments from Elan Pharmaceuticals. He is a graduate of
Rutgers University, US.
Interest in shares
and options
Special responsibilities
358,423 shares and 3,600,000 unlisted options
Chair of the Board.
Member of Audit & Risk Committee
Member of Remuneration & Nomination Committee
Directorship held in other
listed entities (last 3 years)
Noxopharm Limited (ASX:NOX) – resigned 16 July 2019
12
ANNUAL REPORT FY22
Peter Marks
Non-Executive Director, joined the Board in August 2017, resigned 1 August 2022
Peter has over 35 years' experience in corporate advisory and investment banking. Over the
course of his long career, he has specialised in capital raisings, IPOs, cross border, M&A
transactions, corporate underwriting and venture capital transactions for companies in
Australia, the United States and Israel. He has been involved in a broad range of transactions
with a special focus on the life sciences, biotechnology, medical technology and high-tech
segments. Peter has served as both an Executive and Non-Executive Director of a number of
different entities which have been listed on the ASX, NASDAQ, and AIM markets.
Peter is currently a Director of Alterity Therapeutics Limited (ASX:ATH and NASDAQ:ATHE), Non-
Executive Director of Noxopharm Limited (ASX: NOX) and Non-Executive Director of Iris Metals
Limited (ASX:IR1). Peter holds an MBA from the University of Edinburgh, Scotland, a Bachelor of
Economics, a Bachelor of Laws, and a Graduate Diploma in Commercial Law.
Interest in shares
and options
250,000 shares and 2,600,000 unlisted options
Special responsibilities
Member of Audit & Risk Committee
Directorship held in other
listed entities (last 3 years)
Alterity Therapeutics Limited (ASX: ATH) - current
Noxopharm Limited (ASX:NOX) - current
Elsight Limited (ASX:ELS) - current
Iris Metals Limited (ASX:IR1) – current
Fluence Corporation Limited (ASX:FLC) -
resigned 31 March 2020
Christopher Cox
Non-Executive Director, joined the Board in November 2019
Christopher Cox is a Co-Founder and has been a Managing Partner of Population Health
Partners since April 2020. He is also a Senior Vice President of Population Health Investment
Co. Inc (Nasdaq: PHIC). Additionally, Chris is a retired Partner of Cadwalader, Wickersham &
Taft LLP (New York) a position he held from January 2012. He remains a Senior Attorney of the
firm.
Previously the Chairman of Cadwalader’s Corporate Department and a member of its
Management Committee, Chris advises clients on a wide array of corporate and financial
matters, including mergers and acquisitions and restructurings, spin-offs, joint ventures, IP
monetisation’s and other complex financing transactions. From February 2016 to March 2019,
Chris was seconded to The Medicines Company, a global biopharmaceutical company,
where he served as Executive Vice President and Chief Corporate Development Officer and
was responsible for business development and strategy. Before January 2012, Chris was a
partner at Cahill Gordon & Reindel LLP in New York.
Chris also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private
investment holding company with interests in biotechnology, network security and
entertainment.
Chris received both his undergraduate degree and J.D. from the University of Missouri, where
he was also a member of the Missouri Law Review.
Interest in shares
and options
1,425,000 shares and 1,800,000 unlisted options
Special responsibilities
Chair of Remuneration & Nomination Committee
Directorship held in other
listed entities (last 3 years)
N/A
13
NYRADA INC (ASX:NYR)
Marcus Frampton
Non-Executive Director, joined the Board in June 2019
Marcus Frampton currently serves as the Chief Investment Officer of the Alaska Permanent
Fund Corporation (APFC), the US$77 billion sovereign wealth fund for the State of Alaska.
Marcus manages the investment team at APFC and leads all investment decisions related to
APFC’s investment portfolio within the guidelines established by APFC’s Board of Trustees.
Before joining the APFC in 2012, Marcus held positions ranging from Investment Banking
Analyst & Associate at Lehman Brothers (2002-2005), to private equity investing at PCG
Capital Partners (2005-2010), and acted as an executive of a private equity-backed portfolio
company at LPL Financial (2010-2012). In addition to his duties at the APFC, Marcus is also a
shareholder and sits on the board of directors of Scientific Industries, Inc., a leading
manufacturer of laboratory equipment and the owner of intellectual property related to
bioprocessing systems. Marcus graduated from UCLA with a Bachelor’s degree in Business-
Economics and a Minor in Accounting.
Interest in shares
and options
245,075 shares and 1,800,000 unlisted options
Special responsibilities
Chair of Audit & Risk Committee
Directorship held in other
listed entities (last 3 years)
N/A
Rüdiger Weseloh Ph.D.
Non-Executive Director, joined the Board in June 2019
Rüdiger Weseloh is a Senior Director of Business Development at Merck KGaA, Darmstadt,
Germany, where over a period of 15 years he has led more than 80 transactions for its
pharmaceutical division, completing deals across the drug development value chain in the
fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before Merck
KgaA, Rüdiger spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank
AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the
Max-Planck-Institute for Experimental Medicine in Goettingen. He has a university diploma in
Biochemistry from the University of Hannover and a PhD in Molecular Neurobiology, obtained
at the Center for Molecular Neurobiology in Hamburg. Rüdiger also served 5 years on the
Supervisory Board of Cytotools AG, Freiburg, Germany.
Interest in shares
and options
100,000 shares and 1,800,000 unlisted options
Special responsibilities
N/A
Directorship held in other
listed entities (last 3 years)
Cytotools AG (FRA:T50) - resigned in September 2021
14
ANNUAL REPORT FY22
Ian Dixon Ph.D.
Non-Executive Director, joined the Board in September 2020.
Dr Dixon has a PhD in biomedical engineering from Monash University, an MBA from
Swinburne University and professional engineering qualifications. He is also a co-inventor of
Nyrada’s patented drug NYX-330 to treat hypercholesterolemia and atherosclerosis.
Dr Dixon brings to the Board an extensive technical and entrepreneurial background in
founding, building and running technology-based companies, in recognising the potential
commercial value of early-stage drug development, and in understanding the challenges
involved in drug development.
In 2011, Dr Dixon co-founded Cynata Inc, now a subsidiary of ASX-listed Cynata Therapeutics
Ltd (ASX-CYP), a company progressing the commercialisation what has become the
Cymerus stem cell therapy to treat various medical conditions including osteoarthritis, ARDS
and critical limb ischemia. Also a founder director of genetic medicines company Exopharm
Ltd (ASX-EX1) in 2013 and during the last three years Dr Dixon has served as a director of the
following listed companies: Medigard Ltd (ASX-MGZ); Noxopharm Ltd:(ASX-NOX).
Interest in shares
and options
10,114,033 shares, 5,999,400 Performance Shares and
1,800,000 unlisted options
Special responsibilities
Member of Remuneration & Nomination Committee
Directorship held in other
listed entities (last 3 years)
Exopharm Limited (ASX:EX1) -current
Noxopharm Limited (ASX:NOX) - resigned on 31 August 2020
Gisela Mautner
Non-executive Director, joined the Board 1 August 2022
Gisela is an international business leader with significant experience developing and
launching new pharmaceutical products, and delivering successful corporate strategies in
highly competitive global markets. She also has over thirty years’ experience in medical and
scientific research, most recently as the Chief Medical Officer of Noxopharm Ltd (ASX-NOX).
Gisela has held senior positions with Amgen, Bayer, Siemens Medical Solutions and
Merck/MSD generating successful commercial and scientific outcomes. She is currently the
Past-President of the Australian Pharmaceutical Physicians Association (APPA), a Fellow of
the Australasian College of Physician Executives and a Member of the Australian Institute of
Company Directors and the CEO Institute.
Gisela holds an MD from the Technical University of Munich, a PhD from the Ludwig Maximilian
University, an MPH from Harvard University and an MBA from Northwestern University
Chicago.
Interest in shares
and options
N/A
Special responsibilities
N/A
Directorship held in other
listed entities (last 3 years)
Noxopharm Limited (ASX:NOX) - current
Company Secretary - David Franks
David is a Chartered Accountant, Fellow of the Financial Services Institute of Australia, Fellow of the Governance Institute
of Australia, Justice of the Peace, Registered Tax Agent and holds a Bachelor of Economics (Finance and Accounting) from
Macquarie University. With over 25 years in finance and governance (including company secretarial and corporate
finance), David has been CFO, company secretary and director for numerous ASX listed and unlisted public and private
companies, in a range of industries covering energy retailing, software as a service, transport, financial services, oil and
gas / mineral exploration, technology, automotive, software development, wholesale distributions, retail, biotechnology
and healthcare. He has acted in these capacities for Top 200 to small-cap companies listed on ASX, including for
companies with OTC listings. David is also the Company Secretary of Noxopharm. David is also a Non-Executive Director
of Jcurve Solutions Limited (ASX:JCS) and a Director, Principal and shareholder of Automic Group Pty Ltd, a service provider
to the Company.
15
NYRADA INC (ASX:NYR)
Principal activities
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to
treat cardiovascular and neurological diseases. The Company’s two lead programs are focused on Cholesterol-Lowering
and Brain Injury, each targeting market sectors of significant size and unmet clinical need. These programs are developing
an oral, small molecule Cholesterol-Lowering drug, and a drug to reduce secondary brain damage following a stroke or
traumatic brain injury (TBI).
Nyrada is a Company incorporated in the state of Delaware, US and is listed on the Australian Securities Exchange
(ASX:NYR).
Significant changes in the state of affairs
There were no significant changes in the state of affairs of the Consolidated Entity during the financial year.
Financial results
The loss for the Consolidated Entity after providing for income tax amounted to $3,959,661 (30 June 2021: $3,539,253).
The year ended 30 June 2022 operating results included the following:
•
•
Research and Development Tax Incentive refund of $1,048,333 relating to the accrued FY2022 refund (2021:
$2,286,022 relating to the FY2020/2021 refund of $1,309,650 and received FY2019/2020 refund of $976,372).
Research and development costs of $1,835,072 (FY2021: $2,175,050);
• Corporate and administration expenses of $699,653 (FY2021: $895,839);
•
•
•
Share based payment expense of $966,951 (FY2021: $1,111,622);
Professional services expense of $338,841 (FY2021: $509,842); and
Employee benefits expense of $1,000,030 (FY2021: $929,931)
The cash position as at 30 June 2022 was $10,816,039 (30 June 2021: $13,750,743).
Review of operations
During the 2022 financial year, Nyrada continued to advance its two lead drug development programs:
• Cholesterol-Lowering Program: an oral PCSK9 inhibitor drug for the treatment of high blood LDL-cholesterol
levels in patients at risk of cardiovascular disease, where statin drugs are poorly tolerated (monotherapy) or
ineffective (single pill combination treatment).
•
Brain Injury Program: a neuroprotectant drug to reduce the impact of secondary brain injury in patients
following a stroke or TBI, such as can occur following a motor vehicle accident, fall, or sporting injury.
Strong results from both of these programs over the course of the year positions the Company well for the clinical
studies ahead.
Breaking new ground in the development of a once-per-day, oral cholesterol-lowering drug
Nyrada’s oral PCSK9 inhibitor drug creates the potential for a next generation alternative to expensive and inconvenient
PCSK9 injectable drugs. During FY2022, Nyrada’s Cholesterol-Lowering Program continued to deliver impressive
preclinical results.
In August 2021, exploratory analysis results from an in vivo cholesterol efficacy study showed NYX-PCSK9i significantly
increased plasma PCSK9 levels, supporting the mechanism of action of Nyrada’s compound in lowering cholesterol. The
35-day study used a specialised mouse model genetically modified to better reflect the way in which humans metabolise
cholesterol. NYX-PCSK9i was dosed at 50mg/kg as a monotherapy and in combination with the statin drug Lipitor®
(atorvastatin, Pfizer) with no adverse effects identified.
Treatment with NYX-PCSK9i also significantly increased the number of LDL receptors responsible for removing cholesterol
from the bloodstream, with further analysis revealing Nyrada’s compound enhances cholesterol clearance from the body.
16
ANNUAL REPORT FY22
Testing Nyrada’s PCSK9 Inhibitor in a Model of Atherosclerosis
On 19 July 2022, results from a study run by researchers at Duke University Pratt School of Engineering (Duke), using select
candidates from Nyrada’s PCSK9 inhibitor family of compounds were presented at the North American Vascular Biology
Organisation (NAVBO) 2022 Vasculata conference in North Carolina. The study aimed to determine if PCSK9 inhibitors
attenuate inflammation in vascular cells in the early phases of atherosclerosis.
In a human tissue-engineered blood vessel model of atherosclerosis, developed in the lab of Professor George Truskey,
Nyrada’s PCSK9 inhibitor blocked the early stages of atherosclerotic plaque progression, including preventing monocyte
adhesion and suppression of inflammatory cytokines, which are key mediators of the disease process. An optimised
version of NYX-PCSK9i with superior pharmacokinetic parameters (improved absorption and distribution) was evaluated
in this study. Accordingly, this compound will be assessed in Nyrada’s Phase I study in the first half of CY2023.
It is the first time the model has been used to characterise the role of PCSK9 in the early phases of atherosclerosis and the
potential for small molecule inhibitors of PCSK9 to block this process. The researchers at Duke intend to publish the findings
of this study in a peer-reviewed paper.
Preclinical Safety and Toxicity Studies
During the second half of FY2022, an escalation in the number of COVID cases in Shanghai, China led to widespread
lockdowns, which delayed the scale-up manufacture of Nyrada’s drug candidate, as employees of the contract
manufacturing organisation (CMO) engaged by Nyrada were not able to access laboratory worksites. Drug manufacture
was quick to recommence upon Shanghai’s reopening, with the CMO deploying additional personnel and resources to
recover lost time.
Impacted by the lockdowns, the required preclinical safety, pharmacology, and toxicology studies are expected to
commence in H2 CY2022. These studies will evaluate the safety and tolerability of Nyrada’s drug and will be run at Inotiv,
a US based contract research organisation (CRO). Data from these studies will determine the safe starting dose for the
Phase I first-in-human study.
Phase I Study
The primary objective of the Phase I study is to evaluate Nyrada’s drug candidate for safety and tolerability. The study will
be a double-blind, randomised, dose escalation design evaluating the safety, tolerability, and pharmacokinetics of
Nyrada’s leading drug candidate in approximately 56 healthy volunteers aged 18 to 50 years.
A secondary endpoint will assess blood cholesterol levels in cohorts treated for 14 days with Nyrada’s drug candidate as
a preliminary indication of the drug’s efficacy in humans. Favourable results from the Phase I study will position Nyrada
well for a possible Phase II clinical trial, which would provide a comprehensive assessment of the efficacy of Nyrada’s drug
candidate in the target population, patients with a high cholesterol.
As a result of scale-up drug manufacturing delays caused by COVID-related lockdowns in Shanghai, the Phase I first-in
human study is expected to commence during the first half of CY2023.
Objectives
•
Evaluate safety, tolerability, and pharmacokinetics of NYX-PCSK9i
• Measure changes in LDL-cholesterol
Design (subject to
ethics approval)
•
•
Double-blind, randomized, placebo-controlled, dose escalation study
Single ascending oral dose (Cohorts 1-5)
• Once daily oral dose over 14-day treatment period (Cohorts 6, 7)
Participants
Location & Duration
•
•
•
•
•
Pharmacokinetic and pathology samples will be collected at selected time points
over the trial period for all subjects
56 healthy volunteers (18 to 50 years)
7 cohorts (6 active: 2 placebo per cohort)
Study will be conducted at a clinical trial center in Australia
The dosing period will vary between 1 – 14 days
Day 1
Day 2
Day 14
Cohorts 1-5
Cohorts 6-7
Single ascending oral dose
Once daily oral dose
Data
analysis
17
NYRADA INC (ASX:NYR)
Developing a drug to block secondary brain damage following traumatic brain injury or a stroke
Our Brain Injury Program continued to make significant progress during the year. Further optimisation to improve the
overall drug-like properties of Nyrada’s previous brain injury drug candidate NYR-BI01, led to the development of NYR-BI02
and its selection as our preferred drug candidate to take into the clinic. NYR-BI02 has a superior pharmacokinetic profile
to NYR-BI01 and has improved stability and solubility.
We also revealed the biological target for the Brain Injury Program as a class of proteins known as “Canonical” Transient
Receptor Potential, or TRPC ion channels. These channels are present on the surface of brain cells and allow calcium to
enter the cell. Calcium is critical to cell survival, however excess calcium triggers cell death pathways.
Following an injury in the brain, the mechanisms that keep calcium levels in-check fail as they rely on energy, which quickly
depletes. After a brain injury such as a stroke, accident impact or concussion, the TRPC channels remain constantly
activated, allowing sustained calcium entry into the cells leading to cell death.
Nyrada’s brain injury drug candidate NYR-BI02 is a potent blocker of three subtypes of the channel – TRPC3, TRPC6 and
TRPC7, which are present in high levels in brain tissue. By targeting these channels, Nyrada’s brain injury drug candidate
blocks the sustained entry of calcium into the cells reducing secondary brain injury. NYR-BI02 is also able to cross the
blood-brain-barrier, indicating it can reach therapeutic levels in an injured brain.
There are currently no FDA-approved small molecule blockers of TRPC 3/6/7 ion channels.
Possible New Oral Treatment for Concussion
In March 2022, exploratory pharmacokinetic studies undertaken as part of Nyrada’s medicinal chemistry program
revealed excellent oral bioavailability of NYR-BI02, indicating it has the potential to be administered orally to patients who
suffer a concussion.
The convenience of an oral dosage form that can be administered in the field immediately after a concussion injury,
without having to wait for hospitalisation, has the potential to significantly improve patient outcomes. While Nyrada
remains focused on developing a drug to treat moderate to severe TBI and stroke which would be administered
intravenously, given the potential to positively impact patient outcomes and market interest in this area, Nyrada may
pursue NYR-BI02’s development as an oral treatment for concussion as an additional program.
Testing Nyrada’s Brain Injury Drug Candidate in Stroke
The efficacy of Nyrada’s brain injury drug candidate will be evaluated in a well-established preclinical model of stroke.
The model is called the Photothrombotic Model of Ischemia, where localised clot formation is achieved in a specific brain
region, leading to a stroke. This model was previously used by Nyrada to test the efficacy of its first-generation molecule,
which showed a promising efficacy signal.
This work in stroke is outside of the studies being undertaken as part of Nyrada’s collaboration with WRAIR and UNSW.
WRAIR’s focus remains solely on developing a drug to mitigate the impact of TBI on military service members. A key
advantage of the drug that Nyrada is developing is it can be administered to stroke and TBI patients in the same manner,
by way of intravenous dosing over a 3-day period, which is matched to patient emergency hospital admission. It is
anticipated the results of the preclinical stroke model study will be available in Q4 CY2022.
TBI Efficacy Study
Nyrada will initially test the efficacy of its NYR-BI02 molecule as a TRPC 3/6/7 channel blocker in a model of TBI through its
collaboration with WRAIR.
The efficacy study will employ the penetrating traumatic brain injury (PTBI) model which has been developed by the WRAIR
team to emulate penetrating head wounds on the battlefield. The study will involve dosing animals with a vehicle or NYR-
BI02 in a blinded fashion and assessing the injury volume using a specialised MRI technique at UNSW.
The study will include assessment of blood biomarkers that are commonly used in the clinical setting for diagnosis and
prognosis purposes in TBI and stroke patients. The efficacy study will also incorporate assessment techniques commonly
used in animal brain injury models.
This multifaceted study is dependent on the contribution of substantial resources from WRAIR, which has seen some of its
project timelines impacted by the ongoing COVID-19 pandemic. This study is expected to start in CY2023 once the
necessary additional resources from WRAIR can be directed towards this project.
Delays to the start of the TBI efficacy study will not impact the commencement of the Phase I first-in-human study, as
these studies can be run in tandem.
18
ANNUAL REPORT FY22
Preclinical Safety and Toxicity Studies
Safety, pharmacology, and toxicology studies are anticipated to begin in Q3 CY2022. These studies will evaluate the safety
and tolerability of Nyrada’s lead brain injury drug candidate in research models. Data from these studies will determine
the safe starting dose for the Phase I first-in-human study.
Manufacture of the batch of drug to be used in the preclinical and clinical studies has been completed and is now
undergoing formulation development to deliver a dose form suitable for intravenous administration.
The necessary formulation development work is being undertaken at a leading US based CRO from mid-September and
is expected to take between 2 - 6 weeks to complete. This formulation work does not impact on the timing of cell-based
in vitro safety and toxicology studies, which are due to commence in Q3 CY2022. However, this formulation work must be
completed prior to the commencement of the in vivo safety and toxicology studies to ensure optimal drug delivery. The
ongoing COVID-19 pandemic has led to an industry wide constraint on resources and complicated logistics, resulting in a
lack of availability of GLP study slots, making scheduling preclinical work with CROs challenging. The Company is in regular
contact with the CRO to ensure these studies are expedited.
Phase I Study
Pending completion of the FDA mandated preclinical safety and toxicology studies and ethics committee approval of the
trial protocol, recruitment, and dosing of the first participant is expected to commence in H1 CY2023.
The Phase I study will be run in Australia and will evaluate the safety and tolerability of NYR-BI02. The trial participants will
be split into 5 groups of 8, with 6 receiving the drug and 2 receiving a placebo. Blood samples will be drawn several times
throughout the study period and analysed for drug levels. Participants will be monitored for clinical signs throughout the
study duration.
The study will support the development of Nyrada’s drug in both TBI and stroke indications, significantly expanding the
commercial opportunities available to the Company.
Objectives
Design (subject to
ethics approval)
•
•
•
•
•
To assess the safety, tolerability, and pharmacokinetics of NYR-BI02
Randomized, double-blind placebo –controlled, dose escalation design
5 cohorts; 8 participants each cohort; 6:2 active and placebo treatments
3 cohorts will be single ascending doses
2 cohorts will be given continuous infusion doses
Participants
• Male and female healthy volunteers
•
18 – 50 years age
Cohort number
Dose administered
1
2
3
4
5
Low dose single bolus
Medium dose single bolus
High dose
Low dose continuous infusion (72 hrs)
High dose continuous infusion (72 hrs)
Location & Duration
•
•
Study will be conducted at a clinical trial center in Australia
The study duration will vary between 1 – 4 days
Day 1
Day 2
Day 3
Day 7
Day 10
Cohorts 1-3
Bolus delivery
Safety assessment
Cohorts 4-5
Continuous infusion
Safety assessment
19
NYRADA INC (ASX:NYR)
Intellectual Property
Cholesterol-Lowering Program
Nyrada’s medicinal chemistry program continued to generate further promising PCSK9 inhibitor analogues, which
enabled the Company to file a Patent Cooperation Treaty (PCT) application for new generation PCSK9 inhibitor
compounds in December 2021. A PCT application makes it possible to seek protection for an invention simultaneously in a
large number of countries by filing a single “international” patent application, instead of filing several separate national
or regional applications. This application builds on the patent granted by the US Patent and Trademark Office, as
announced on 30 July 2021.
In July 2022, the European Patent Office granted a composition of matter patent for the Company’s novel compounds
inhibiting PCSK9, providing protection for Nyrada’s intellectual property relating to its PCSK9 inhibitor technology until 16
March 2038. Nyrada now has patent protection for the compounds in both the US and European Union.
Brain Injury Program
In May 2022, Nyrada filed a provisional patent covering a library of molecules, including NYR-BI02, that block TRPC ion
channels. It is anticipated that the patent will have coverage firstly in Australia, followed by Europe and US.
Board Changes
In August 2022, Dr. Gisela Mautner was appointed to the Board as a non-executive director. Dr. Mautner is a medical doctor
and brings over 20 years pharmaceutical industry experience encompassing all aspects of drug development, from
clinical research through to product commercialisation. She is a seasoned senior leader, having held positions at MSD
(Merck), Bayer and Amgen, where she successfully launched several new drugs in different therapeutic areas, including
in cardiovascular diseases.
In addition, Peter Marks retired from his role as a non-executive director on the Board to pursue a range of other interests,
having supported Nyrada through its IPO and key first years as a listed company.
COVID-19 Pandemic
Nyrada retained the remote working model we adopted early on in the COVID-19 pandemic, while maintaining access to
a shared office for regular in person meetings. Greater flexibility in how and where our employees choose to work continues
to benefit team morale, as well as enhance productivity while also keeping office overhead costs low. It also means little
to no disruption to the Company’s operations when health authorities issue work from home recommendations during an
increase in COVID-19 case numbers.
Other
In January 2022, Nyrada received an A$1.3 million cash rebate (“R&D rebate”) from the Australian Federal Government’s
Research & Development (R&D) tax incentive program. The R&D rebate relates to expenditure incurred on eligible R&D
activities conducted during the 2021 financial year, in respect of Nyrada’s preclinical work for its Cholesterol-Lowering and
Brain Injury drug development programs. The amount received will partially fund the progression of these two programs
to Phase I clinical trials and the working capital requirements of Nyrada Inc.
Financial Position
Cash and cash equivalents
Net assets / total equity
Contributed equity
Accumulated losses
2022
$
2021
$
10,816,039
13,750,743
11,498,916
14,491,626
25,320,332
25,320,332
(19,515,280)
(15,555,619)
The Directors believe the Consolidated Entity is in a strong and stable financial position to expand its current operations.
20
ANNUAL REPORT FY22
Liquidity and capital resources
Nyrada ended the financial year with cash of $10,816,039 and anticipates to receive an Research and Development tax
incentive refund for the FY2022 of $1,048,333 following 30 June 2022, further boosting capital resources.
Matters subsequent to the end of the financial year
On 1 August 2022 the Company announced the appointment of Dr. Gisela Mautner as a Non-Executive Director to its Board
and retirement of Peter Marks.
No other matters or circumstances have arisen since 30 June 2022 that has significantly affected, or may significantly
affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in
future financial years.
Future developments, prospects, and business strategies
Disclosure of information regarding likely developments in the operations of the Company in future financial years and
the expected results of those operations is likely to result in unreasonable prejudice to the Company. Information on future
developments, prospects, and business strategies have only been referred to in the Chairman’s Letter and CEO Report. For
further information on the Company’s business strategies and material risks, refer also to the Prospectus which is available
on the Company website or ASX Announcements.
Environmental regulation
The Consolidated Entity is not subject to any significant environmental regulation under Australian Commonwealth or
State law.
Directors’ shareholdings
In this section, reference is made to Share ownership. The instruments registered for trade on the Australian Securities
Exchange are CHESS Depositary Interests (CDIs). One CDI is equivalent to one Share, being Class A Common Stock. The
following table sets out each director’s relevant interest in shares, debentures, and rights or options in shares or Directors
of the Company or a related body corporate as at the date of this report:
Share Number
Options Number
Performance Shares
John Moore
Peter Marks
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
Gisela Mautner
358,423
250,000
100,000
245,075
1,425,000
10,114,033
-
3,600,000
2,600,000
1,800,000
1,800,000
1,800,000
1,800,000
-
-
-
-
-
-
5,999,400
-
Options Granted
There were no options granted during the financial year.
21
NYRADA INC (ASX:NYR)
Unissued Common Stock
Details of unissued Common Stock, interests under option and performance shares as at the date of this report are
as follows:
Type of Security
Number
Exercise price
Expiry date
Performance shares
18,000,000
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
Unlisted options
6,000,000
2,000,000
4,000,000
4,000,000
5,000,000
5,000,000
3,600,000
3,600,000
3,600,000
800,000
900,000
4,000,000
2,000,000
2,000,000
1,200,000
600,000
600,000
600,000
N/A1
0.20
0.20
0.22
TBC2
TBC2
TBC2
0.24
TBC3
TBC3
0.24
TBC3
0.40
0.60
0.90
TBC3
TBC3
TBC3
TBC3
25/11/2024
30/06/2024
25/11/2022
16/01/2025
5 years from the vesting date
5 years from the vesting date
5 years from the vesting date
25/11/2023
25/11/2024
25/11/2025
16/01/2023
3 years from the vesting date
29/06/2026
29/06/2026
29/06/2026
3 years from the vesting date
18/01/2024
18/01/2025
18/01/2026
1
2
3
Performance shares convert when specified milestones are achieved, these milestones are outlined in note 9 of the financial
statements.
The exercise price is the higher of
•
100% of the Fair Market Value (as defined in the Company’s Stock Incentive Plan) of the Shares on the date that Option is
granted; and
an amount equal to 110% of the volume-weighted average price of the CDIs for the period of 10 trading days immediately prior
to the date on which that Option vests.
•
The exercise price is the higher of
•
100% of the Fair Market Value (as defined in the Company’s Stock Incentive Plan) of the Shares on the date that Option is
granted; and
an amount equal to 120% of the volume-weighted average price of the CDIs for the period of 10 trading days immediately prior
to the date on which that Option vests.
•
The holders of these options and performance shares do not have the right to participate in any share issue or interest
issue of the Company or of any other body corporate or registered scheme.
Dividends
There were no dividends paid, recommended, or declared during the current or previous financial year.
22
ANNUAL REPORT FY22
Indemnity and insurance of officers
As permitted under Delaware law, Nyrada indemnifies its Directors and certain officers and is permitted to indemnify
employees for certain events or occurrences that happen by reason of their relationship with, or position held at, Nyrada.
The Company’s Certificate of Incorporation and Bylaws provide for the indemnification of its Directors, officers, employees
and other agents to the maximum extent permitted by the Delaware General Corporation Law.
Nyrada has entered into indemnification agreements with its Directors and certain officers to this effect, including the
advancement of expenses incurred in legal proceedings to which the Director or officer was, or is threatened to be made,
a party by reason of the fact that such Director or officer is or was a Director, officer, employee or agent of Nyrada, provided
that such a Director or officer acted in good faith and in a manner that the Director or officer reasonably believed to be in,
or not opposed to, the Company’s best interests. At present, there is no pending litigation or proceedings involving a
Director or officer for which indemnification is sought, nor is the Company aware of any threatened litigation that may
result in claims for indemnification.
Nyrada maintains insurance policies that indemnify the Company’s Directors and officers against various liabilities that
might be incurred by any Director or officer in his or her capacity as such. The premium paid has not been disclosed as it
is subject to confidentiality provisions under the insurance policy.
Indemnity and insurance of auditor
The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the
Company or any related entity against a liability incurred by the auditor.
During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the
Company or any related entity.
Meetings of Directors
The following table sets out the number of directors’ meetings (including meetings of committees of Directors) held during
the financial year and the number of meetings attended by each director (while they were a Director or committee
member).
Board of
Directors
Audit & Risk
Committee
Remuneration &
Nomination Committee
Attended
Held
Attended
Held
Attended
Held
John Moore
Peter Marks
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
6
6
6
6
6
6
6
6
6
6
6
6
2
2
-
2
-
-
2
2
-
2
-
-
1
-
-
-
1
1
1
-
-
-
1
1
Proceedings on behalf of the Company
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf
of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility
on behalf of the Company for all or part of those proceedings.
23
NYRADA INC (ASX:NYR)
Non-audit services
There were no non-audit services provided during the financial year by the auditor.
In the event non-audit services are provided by the auditor, the Board has established procedures to ensure the provision
of non-audit services is compatible with the general standard of independence for auditors. These include:
•
•
all non-audit services are reviewed and approved to ensure they do not impact the integrity and objectivity of
the auditor; and
non-audit services do not undermine the general principles relating to auditor independence as set out in APES
110 ‘Code of Ethics for Professional Accountants (including Independence Standards)’ issued by the Accounting
Professional & Ethical Standards Board, including reviewing or auditing the auditor’s own work, acting in a
management or decision-making capacity for the Company, acting as an advocate for the Company or jointly
sharing economic risks and rewards.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this Directors' report.
Presentation Currency
The functional and presentation currency of the Company is Australian Dollars (AUD). The financial report is presented in
AUD Dollars with all references to dollars, cents, or $’s in these financial statements presented in AUD currency, unless
otherwise stated.
Jurisdiction of Incorporation
Nyrada is a company incorporated in the State of Delaware in the United States and registered in Australia as a foreign
company. As a foreign company registered in Australia, Nyrada is subject to different reporting and regulatory regimes
than Australian public companies.
Corporate Governance Statement
The Company's corporate governance statement is located at the Company's website:
https://www.nyrada.com/site/About-Us/corporate-governance
Required statements
•
•
•
•
•
Nyrada is not subject to charters 6, 6A, and 6C of the Corporations Act dealing with the acquisition of its shares
(including substantial holdings and takeovers).
The Company’s securities are not quoted on any exchange other than the ASX.
From the time of the Company’s admission to the ASX until 30 June 2022, the Company has used the cash and
assets in a form readily convertible to cash, that it had at the time of admission, in a way that is consistent with
its business objectives at that time.
Under the Delaware General Corporation Law, shares are generally freely transferable subject to restrictions
imposed by US federal or state securities laws, by the Company’s certificate of incorporation or bylaws, or by an
agreement signed with the holders of the shares at issue. The Company’s amended and restated Certificate of
Incorporation and by-laws do not impose any specific restrictions on transfer. The Company’s CDIs were issued
in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities
Act) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under
the Securities Act or the laws of any state or other jurisdiction in the US.
As a result of relying on the Regulation S exemption, the CDIs are ‘restricted securities’ under Rule 144 of the
Securities Act. This means that you are unable to sell the CDIs into the US, or to a US person for the foreseeable
future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the
CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions,
all CDIs issued bear a ‘FOR US’ designation on the ASX. This designation restricts any CDIs from being sold on the
ASX to US persons. However, you are still able to freely transfer your CDIs on the ASX to any person other than a
US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with
the Securities Act.
24
ANNUAL REPORT FY22
Remuneration report (audited)
Nyrada Inc is a Delaware incorporated company that is listed on the Australian Securities Exchange (ASX) and as such is
subject to remuneration disclosure requirements that are suitable for reporting in both Australia and the United States.
This remuneration report forms part of the Directors’ Report and has been prepared using the requirements of section
300A of the Australian Corporations Act 2001 as a proxy to determine the contents that the Board has chosen to report.
This remuneration, which forms part of the Directors’ report, sets out information about the remuneration of Nyrada Inc.'s
key management personnel for the financial year ended 30 June 2022. The term ‘key management personnel’ refers to
those persons having authority and responsibility for planning, directing, and controlling the activities of the Consolidated
Entity, directly or indirectly, including any director (whether executive or otherwise) of the Consolidated Entity. The
prescribed details for each person covered by this report are detailed below under the following headings:
•
•
•
•
•
Key Management Personnel
Remuneration Policy
Relationship between the Remuneration Policy and Consolidated Entity performance
Remuneration of Key Management Personnel
Key terms of employment contracts.
Key Management Personnel
The Directors and other Key Management Personnel (KMP) of the Group during the financial year were:
Non-Executive Directors
John Moore
Peter Marks
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
Executive employees
James Bonnar
Position
Non-executive Chairman
Non-executive Director
Non-executive Director
Non-executive Director
Non-executive Director
Non-executive Director
Position
Chief Executive Officer
25
NYRADA INC (ASX:NYR)
Remuneration Policy
The Company has a Remuneration and Nomination Committee, which consists of Christopher Cox (Chair of the
Remuneration Committee), Ian Dixon, and John Moore. The remuneration policy, which is set out below, is designed to
promote superior performance and long-term commitment to the Company. An overview of the Remuneration &
Nomination Committee is outlined below.
The Remuneration & Nomination Committee establishes, amends, reviews and approves the compensation and equity
incentive plans with respect to senior management and employees of the Company, including determining individual
elements of the total compensation of the Chief Executive Officer and other members of senior management. The
Remuneration & Nomination Committee is also responsible for reviewing the performance of the Company’s executive
officers with respect to these elements of compensation. It recommends the Director nominees for each annual general
meeting and ensures that the Audit & Risk Committee and Remuneration & Nomination Committee have the benefit of
qualified and experienced directors.
Non-executive Director remuneration
Under the Company’s Bylaws, the Directors decide the total amount paid to each non-executive Director for their services.
However, under the ASX Listing Rules, the total amount paid to all non-executive Directors must not exceed in any financial
year the amount fixed in a general meeting of the Company. This amount is capped under the Bylaws at US$500,000
(exclusive of securities) per annum. Any increase to the aggregate amount needs to be approved by CDI Holders. The
Directors will seek CDI Holder approval from time to time as appropriate. The aggregate annual sum does not include any
special remuneration which the Board may grant to the Directors for special exertions or additional services performed
by a Director for or at the request of the Company, which may be made in addition to or in substitution for the
Director’s fees.
The Directors set the individual non-executive director fees within the overall limit approved by CDI Holders. Non-executive
directors are not provided with retirement benefits.
Executive Director remuneration
Executive directors receive a base remuneration which is at market rates and may be entitled to performance-based
remuneration, which is determined on an annual basis. Overall remuneration policies are subject to the discretion of the
board and can be changed to reflect competitive and business conditions where it is in the interests of the Group and
shareholders to do so. Executive remuneration and other terms of employment are reviewed annually by the board having
regard to the performance, relevant comparative information and expert advice.
The Board’s Remuneration Policy reflects its obligation to align executive remuneration with shareholders’ interests and to
retain appropriately qualified executive talent for the benefit of the Consolidated Entity. The main principles are:
•
•
•
remuneration reflects the competitive market in which the Consolidated Entity operates;
individual remuneration should be linked to performance criteria if appropriate; and
executives should be rewarded for both financial and non-financial performance.
The total remuneration of executives consists of the following:
•
•
•
•
salary – executives receive a fixed sum payable monthly in cash plus superannuation at 10% of salary;
cash at-risk component – executives may participate in share and option schemes generally made in
accordance with thresholds set in plans approved by shareholders if deemed appropriate. However, the board
considers it appropriate to issue shares and options to executives outside of approved schemes in exceptional
circumstances;
other benefits – executives may, if deemed appropriate by the board, be provided with a fully expensed mobile
phone and other forms of remuneration; and
performance bonus.
The Board has not formally engaged the services of a remuneration consultant to provide recommendations when setting
the remuneration received by directors or other key management personnel during the financial year.
26
Relationship between the remuneration policy and Consolidated Entity performance
The Board considers that at this time, evaluation of the Consolidated Entities financial performance using generally
accepted measures such as profitability, total shareholder return or benchmarking are not relevant as the Consolidated
Entity is in the pre-clinical phase of drug development.
ANNUAL REPORT FY22
Short-term
employee benefits
Bonus
Other
Post-
employment
benefits
Super-
annuation
Share-based
payments
Options and
performance
shares2
$
Total
$
83,698
264,833
41,849
41,849
41,849
41,849
118,124
124,661
118,482
118,482
177,275
253,852
$
-
-
-
-
-
-
$
-
-
-
-
-
-
21,093
27,375
141,928
464,146
21,093
27,375
570,297
1,462,580
1
2.
Rüdiger was remunerated $13,144 for services provided outside of his Director role for R&D consulting. The fees paid to Rüdiger were
at market rates.
The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is
apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and
this amount does not represent a cash benefit to the key management personnel.
2022
Non-Executive Directors
John Moore
Peter Marks
Rüdiger Weseloh1
Marcus Frampton
Christopher Cox
Ian Dixon
Salary
& fees
$
181,135
76,275
82,812
76,633
76,633
76,577
Executive Employees
James Bonnar (CEO)
273,750
Total
843,815
2021
Non-Executive Directors
John Moore
Graham Kelly1
Peter Marks
Rüdiger Weseloh3
Marcus Frampton
Christopher Cox
Ian Dixon2
Salary
& fees
$
130,101
5,189
49,522
66,906
51,887
51,887
40,800
Executive Employees
James Bonnar (CEO)
277,177
Total
673,469
$
-
-
-
-
-
-
-
-
$
-
-
-
-
-
-
-
-
-
Short-term
employee benefits
Bonus
Other
Post-
employment
benefits
Super-
annuation
$
-
Share-based
payments
Options and
performance
shares5
$
Total
$
182,564
312,665
493
191,780
197,462
-
-
-
-
-
91,282
91,282
91,282
91,282
140,804
158,188
143,169
143,169
149,2054
190,005
$
-
-
-
-
-
-
-
18,163
18,163
23,948
24,441
58,757
378,045
947,434
1,663,507
1
2.
3.
4.
5.
Graham Kelly resigned as Non-Executive Director on 8 September 2020.
Ian Dixon was appointed as Non-Executive Director on 8 September 2020.
Rüdiger Weseloh was remunerated $22,268 for services provided outside of his Director role for R&D consulting. The fees paid were
at market rates.
The share based payment in relation to performance shares held by related party Altnia Holding Pty Ltd of $80,037 was incorrectly
omitted in the 2021 Annual Report. The amount of $149,205 is the restated amount.
The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is
apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and
this amount does not represent a cash benefit to the KMP.
27
NYRADA INC (ASX:NYR)
Key terms of employment contracts
James Bonnar
The Company has entered into an Executive Services Agreement (ESA) with James Bonnar (Bonnar).
Under the ESA, Bonnar is employed by the Company to provide services to the Company as Chief Executive Officer on a
full-time basis. The Company will remunerate Bonnar for his services with a base remuneration of $301,125 per annum,
inclusive of superannuation and subject to annual review by the Company.
The ESA may be terminated by either the Company or Bonnar for any reason on 6 months’ written notice, in which case
the Company can elect for Bonnar to serve out all or part of that notice period and/or to pay Bonnar an amount in lieu of
continuing his employment during all or part of that notice period.
The ESA may also be terminated by the Company summarily at any time if Bonnar breaches a material term of the ESA,
or engages in any act or omission constituting serious misconduct, in which case the Company need not make any
payment to Bonnar other than accrued entitlements.
Any discoveries and inventions made or discovered by Bonnar during the term of the ESA which relate to the Company's
business must be disclosed to the Company and will remain the sole property of the Company.
James Bonnar is also subject to restrictions in relation to:
•
•
the use of confidential information during and after his employment with the Company; and
being directly or indirectly involved in a competing business during and after his employment with the Company,
on terms which are considered standard for agreements of this nature.
Otherwise, the ESA is on terms considered standard for agreements of this nature.
Non-executive Directors
The Company maintains a Director Services Agreement with each Non-Executive Director. The Directors’ fees currently
agreed to be payable by the Company under the Director Services Agreements are set out below:
Name
John Moore
Peter Marks
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
Annual Non-Executive Director Fees
US$120,000
US$50,000
US$50,000
US$50,000
US$50,000
US$50,000
Further, if a Director is a member of the Audit & Risk Committee and/or the Remuneration & Nomination Committee, the
Company has agreed to pay that Director an additional US$5,000 per annum for each committee in respect of which that
Director is a member. All Directors’ fees are exclusive of any superannuation that is required by law to be made by the
Company.
On appointment to the board, all non-executive Directors are required to sign a letter of appointment with the Company.
The letter of appointment summarises the Board policies and terms, including compensation relevant to the office or
director.
28
ANNUAL REPORT FY22
Key Management Personnel equity holdings
Shares of Nyrada Inc.
Balance at
Granted as
Net other
Balance on
Balance at
1 July
compensation Additions
change
resignation
30 June
2022
No.
No.
No.
No.
No.
No.
Non-Executive Directors
John Moore
Peter Marks
358,423
250,000
Rüdiger Weseloh
100,000
Marcus Frampton
245,075
Christopher Cox
1,425,000
Ian Dixon
10,114,033
Executive Employees
James Bonnar
141,923
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
358,423
250,000
100,000
245,075
1,425,000
10,114,033
141,923
Balance at
Granted as
1 July
compensation Additions
Net other
change3
Balance on
Balance at
resignation
30 June
2021
No.
No.
No.
No.
No.
No.
Non-Executive Directors
John Moore
Graham Kelly1
Peter Marks
197,500
616,551
50,000
Rüdiger Weseloh
-
Marcus Frampton
110,075
Christopher Cox
800,000
Ian Dixon2
-
Executive Employees
James Bonnar
65,000
-
-
-
-
-
-
-
-
-
-
-
-
-
-
200,000
100,000
135,000
625,000
9,921,725
192,308
-
76,923
160,923
-
358,423
-
(616,551)
-
-
-
-
-
-
-
250,000
100,000
245,075
1,425,000
10,114,033
141,923
1
2
3
Graham Kelly resigned as Non-Executive Director on 8 September 2020.
Ian Dixon was appointed as Non-Executive Director on 8 September 2020. On appointment Ian Dixon held 9,921,725 shares.
Net other changes relate to participation in Placement and on-market purchases of issued shares / CDIs.
29
NYRADA INC (ASX:NYR)
Options of Nyrada Inc.
Granted as
Balance
Balance
compens-
Exercised/
Balance on
Balance
vested at
at 1 July
ation
Cancelled
resignation
at 30 June
30 June
Options
vested
during
year
2022
No.
No.
No.
No.
No.
No.
No.
Non-Executive Directors
John Moore
3,600,000
Peter Marks
2,600,000
Rüdiger Weseloh
1,800,000
Marcus Frampton
1,800,000
Christopher Cox
1,800,000
Ian Dixon
-
Executive Employee
James Bonnar
600,000
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3,600,000
1,200,000
1,200,000
2,600,000
1,400,000
600,000
1,800,000
600,000
600,000
1,800,000
600,000
600,000
1,800,000
600,000
600,000
1,800,000
1,800,000
-
-
-
-
Granted as
Balance
Balance
compens-
Exercised/
Balance on
Balance
vested at
at 1 July
ation
Cancelled
resignation
at 30 June
30 June
Options
vested
during
year
2021
No.
No.
No.
No.
No.
No.
No.
Non-Executive Directors
John Moore
3,600,000
Graham Kelly
18,037,293
Peter Marks
2,600,000
Rüdiger Weseloh
1,800,000
Marcus Frampton
1,800,000
Christopher Cox
1,800,000
-
-
-
-
-
-
Ian Dixon
-
1,800,000
Executive Employee
James Bonnar
600,000
1,200,000
-
3,600,000
1,200,000
1,200,000
(18,037,293)
-
-
-
-
-
-
-
-
-
2,600,000
1,400,000
600,000
1,800,000
600,000
600,000
1,800,000
600,000
600,000
1,800,000
600,000
600,000
1,800,000
1,800,000
-
-
-
-
-
-
-
-
-
-
-
-
30
Performance Shares
ANNUAL REPORT FY22
Options
Balance
vested
Balance
Granted as
Exercised/C
Balance on
Balance
vested at
during
at 1 July
compensation
ancelled
resignation
at 30 June
30 June
year
2022
No.
No.
No.
No.
No.
No.
No.
Non-Executive Directors
John Moore
Peter Marks
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
Executive Employee
James Bonnar
-
-
-
-
-
-
-
-
-
-
-
-
5,999,400
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5,999,400
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Balance
Granted as
Exercised/
Balance on
Balance
vested at
during
at 1 July
compensation
Cancelled
resignation
at 30 June
30 June
year
2021
No.
No.
No.
No.
No.
No.
No.
Options
Balance
vested
Non-Executive Directors
John Moore
Graham Kelly
Peter Marks
Rüdiger Weseloh
Marcus Frampton
Christopher Cox
Ian Dixon
Executive Employee
James Bonnar
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5,999,400
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5,999,400
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ian Dixon held all performance shares on 1 July 2020, prior to being appointed as Non-Executive Director on
8 September 2020.
The performance shares table reporting key management personnel’s holdings was incorrectly omitted in the 2021
Annual Report.
End of Remuneration report.
This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.
On behalf of the Directors
John Moore
Non-Executive Chairman
29 August 2022
31
AUDITOR’S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE
CORPORATIONS ACT 2001 TO THE DIRECTORS OF NYRADA INC
I declare that, to the best of my knowledge and belief, during the year ended 30 June 2022 there have
been:
— no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in
relation to the audit; and
— no contraventions of any applicable code of professional conduct in relation to the audit.
William Buck Audit (Vic) Pty Ltd
ABN: 59 116 151 136
N. S. Benbow
Director
Melbourne, 29th August 2022
Level 20, 181 William Street, Melbourne VIC 3000
+61 3 9824 8555
vic.info@williambuck.com
williambuck.com.au
William Buck is an association of firms, each trading under the name of William Buck
across Australia and New Zealand with affiliated offices worldwide.
Liability limited by a scheme approved under Professional Standards Legislation.
Nyrada Inc
Independent auditor’s report to members
REPORT ON THE AUDIT OF THE FINANCIAL REPORT
Opinion
We have audited the financial report of Nyrada Inc (the Company) and its controlled entities (together, the
Group), which comprises the consolidated statement of financial position as at 30 June 2022, the
consolidated statement of profit or loss and other comprehensive income, the consolidated statement of
changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the
financial statements, including a summary of significant accounting policies and other explanatory
information, and the directors’ declaration.
In our opinion, the accompanying financial report of the Group, is in accordance with the Corporations Act
2001, including:
i. giving a true and fair view of the Group’s financial position as at 30 June 2022 and of its financial
performance for the year ended on that date; and
ii. complying with Australian Accounting Standards and the Corporations Regulations 2001.
Basis for Opinion
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those
standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Report section
of our report. We are independent of the Group in accordance with the auditor independence requirements
of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical
Standards Board’s APES 110 Code of Ethics for Professional Accountants (including Independence
Standards) (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled
our other ethical responsibilities in accordance with the Code.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our
opinion.
Key Audit Matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our
audit of the financial report of the current period. These matters were addressed in the context of our audit
of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate
opinion on these matters.
Level 20, 181 William Street, Melbourne VIC 3000
+61 3 9824 8555
vic.info@williambuck.com
williambuck.com.au
William Buck is an association of firms, each trading under the name of William Buck
across Australia and New Zealand with affiliated offices worldwide.
Liability limited by a scheme approved under Professional Standards Legislation.
ACCOUNTING FOR SHARE-BASED PAYMENTS
Area of focus
How our audit addressed it
For the year ended 30 June 2022 there were no
new share-based payment arrangements;
however vesting charges continued to accrue to
the profit or loss in-respect of prior period share-
based payment arrangements. These also
impacted disclosures in the Remuneration
Report and in Related Party transaction
arrangements.
As such, our audit procedures involved:
— Rolling forward share-based payment
arrangement from the prior year;
— Ensuring that none of these arrangements
were modified by examining board minutes,
public announcements and through our
discussions with management; and
— Recomputing the vesting charge applied from
those arrangements.
We also ensured that these existing share-
based payment arrangements were
appropriately disclosed in the financial report
and Remuneration Report.
The Group actively encourages its employees, key
management personnel and other contracting parties
to be aligned with overall shareholder value through
share-based payment arrangements in accordance
with AASB 2 Share-based Payment.
Its share-based payment arrangements in periods
leading up to and for the year ended 30 June 2022
took the form of share options and performance
rights.
These arrangements have some complexity in their
calculation, namely around the following:
— The determination of their grant date, which sets
the value of the share-based payment
arrangement;
— Applying a valuation model that is appropriate in
the context of the vesting terms of the
arrangement, particularly concerning any market
and non-market based vesting terms;
— Applying inputs into the valuation models,
particularly concerning the determination of
expected volatility calculations; and
— Assessing the appropriateness of the vesting
charge of each share-based payment arrangement
taken to the profit or loss during the year.
This is a key audit matter as vesting charges
concerning key management personnel remuneration
are recorded in the Remuneration Report, which
accompanies these financial statements.
Other Information
The directors are responsible for the other information. The other information comprises the information in
the Group’s annual report for the year ended 30 June 2022 but does not include the financial report and the
auditor’s report thereon.
Our opinion on the financial report does not cover the other information and we do not express any form of
assurance conclusion thereon.
In connection with our audit of the financial report, our responsibility is to read the other information and, in
doing so, consider whether the other information is materially inconsistent with the financial report or our
knowledge obtained in the audit or otherwise appears to be materially misstated.
If, based on the work we have performed, we conclude that there is a material misstatement of this other
information, we are required to report that fact. We have nothing to report in this regard.
Responsibilities of the Directors for the Financial Report
The directors of the Company are responsible for the preparation of the financial report that gives a true
and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for
such internal control as the directors determine is necessary to enable the preparation of the financial
report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
In preparing the financial report, the directors are responsible for assessing the ability of the Group to
continue as a going concern, disclosing, as applicable, matters related to going concern and using the
going concern basis of accounting unless the directors either intend to liquidate the Group or to cease
operations, or has no realistic alternative but to do so.
Auditor’s Responsibilities for the Audit of the Financial Report
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free
from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our
opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted
in accordance with the Australian Auditing Standards will always detect a material misstatement when it
exists. Misstatements can arise from fraud or error and are considered material if, individually or in the
aggregate, they could reasonably be expected to influence the economic decisions of users taken on the
basis of this financial report.
A further description of our responsibilities for the audit of these financial statements is located at the
Auditing and Assurance Standards Board website at:
https://www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf
This description forms part of our independent auditor’s report.
Report on the Remuneration Report
Opinion on the Remuneration Report
We have audited the Remuneration Report included in the directors’ report for the year ended 30 June
2022.
In our opinion, the Remuneration Report of Nyrada Inc for the year ended 30 June 2022 complies with
section 300A of the Corporations Act 2001.
Responsibilities
The directors of the Company are responsible for the preparation and presentation of the Remuneration
Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an
opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing
Standards.
William Buck Audit (Vic) Pty Ltd
ABN 59 116 151 136
N. S. Benbow
Director
Melbourne, 29th August 2022
“In the US, 4.8 million people are evaluated in
emergency departments for TBI each year, with
TBI being diagnosed in approximately 2% of total
emergency department visits, hospitalisations,
and deaths. This is not just a civilian issue, with
1 in 5 US military service members reporting
experiencing a TBI during active duty. ”
NYRADA INC (ASX:NYR)
Consolidated Statement of Profit or Loss and
Other Comprehensive Income
For the year ended 30 June 2022
Revenue
Other income
R&D grant revenue
Total revenue
Expenses
Notes
5
6
2022
$
2021
$
59,241
53,989
1,048,333
2,286,022
1,107,574
2,340,011
Employee benefits expense - share based payments
(966,951)
(1,111,622)
Professional services expenses
Employee benefits expense
(338,841)
(509,842)
(1,000,030)
(929,931)
Depreciation and amortisation expense
(4,734)
(1,811)
Research and development costs
Other expenses
Finance costs
(1,835,072)
(2,175,050)
(220,568)
(249,564)
(1,386)
(5,605)
Corporate and administration expenses
(699,653)
(895,839)
Total expenses
(5,067,235)
(5,879,264)
Loss before income tax expense
(3,959,661)
(3,539,253)
Income tax expense
12
-
-
Loss after income tax expense for the year attributable to the
owners of Nyrada Inc.
(3,959,661)
(3,539,253)
Other comprehensive income for the year, net of tax
-
-
Total comprehensive income for the year attributable to the
owners of Nyrada Inc.
(3,959,661)
(3,539,253)
Basic loss per share
Diluted loss per share
18
18
$
(0.03)
(0.03)
$
(0.03)
(0.03)
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with
the accompanying notes.
38
Consolidated Statement of Financial Position
ANNUAL REPORT FY22
As at 30 June 2022
Assets
Current assets
Notes
2022
$
2021
$
Cash and cash equivalents
10,816,039
13,750,743
Trade, other receivables and prepayments
7
1,153,725
1,360,821
Total current assets
Non-current assets
Plant and equipment
Intangibles
Total non-current assets
Total assets
Liabilities
Current liabilities
Trade and other payables
8
11,969,764
15,111,564
8,729
35,901
44,630
8,443
37,000
45,443
12,014,394
15,157,007
382,955
89,169
472,124
43,354
43,354
588,029
77,352
665,381
-
-
515,478
665,381
11,498,916
14,491,626
9
10
25,320,332
25,320,332
5,693,864
4,726,913
(19,515,280)
(15,555,619)
11,498,916
14,491,626
Employee benefits
Total current liabilities
Non-current liabilities
Employee benefits
Total non-current liabilities
Total liabilities
Net assets
Equity
Issued capital
Reserves
Accumulated losses
Total equity
The above consolidated statement of financial position should be read in conjunction with the accompanying notes.
39
NYRADA INC (ASX:NYR)
Consolidated Statement of Changes in Equity
For the Year Ended 30 June 2021
Balance at 1 July 2020
15,607,349
2,204,324
(12,285,073)
5,526,600
Issued
Accumulated
capital
Reserves
losses
Total equity
$
$
$
$
Loss after income tax expense for the year
Other comprehensive income for the year, net of tax
Total comprehensive income for the year
Transactions with owners in their capacity as owners:
Issue of Common Stock
Issuance of common stock - Advisors
Share issue costs
-
-
-
11,870,579
304,615
(782,537)
-
-
-
-
-
-
Share based payments - Broker options
(1,214,494)
1,214,494
Share based payments - reclassification in share capital
(648,332)
648,332
Share based payments - exercise of options
183,152
(183,152)
(3,539,253)
(3,539,253)
-
-
(3,539,253)
(3,539,253)
-
-
-
-
-
-
11,870,579
304,615
(782,537)
-
-
-
-
Share based payments - lapse of options
Share based payments – vesting
-
-
(268,707)
268,707
1,111,622
-
1,111,622
Balance at 30 June 2021
25,320,332
4,726,913
(15,555,619)
14,491,626
Balance at 1 July 2021
25,320,332
4,726,913
(15,555,619)
14,491,626
Loss after income tax expense for the year
Other comprehensive income for the year, net of tax
Total comprehensive income for the year
Transactions with owners in their capacity as owners:
-
-
-
-
-
-
(3,959,661)
(3,959,661)
-
-
(3,959,661)
(3,959,661)
Share based payments – vesting
-
966,951
-
966,951
Balance at 30 June 2022
25,320,332
5,693,864
(19,515,280)
11,498,916
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.
40
ANNUAL REPORT FY22
Consolidated Statement of Cash Flows
For the year ended 30 June 2022
Notes
2022
$
2021
$
Cash flows from operating activities
Payments to suppliers and employees (inclusive of GST)
(4,292,579)
(4,878,622)
R & D tax incentive received
Interest received
1,309,650
2,051,785
13,830
3,989
Cash receipts from other government grants
5
45,411
50,000
Net cash used in operating activities
(2,923,688)
(2,772,848)
Cash flows from investing activities
Payments for plant and equipment
Net cash used in investing activities
Cash flows from financing activities
Repayment of related party loans
Proceeds from issue of Common Stock
(4,756)
(5,000)
(4,756)
(5,000)
-
-
(342,322)
11,870,579
Proceeds from other financing activities
(44,521)
44,521
Transaction costs relating to issue of Common Stock
(224,440)
(234,286)
Net cash from/(used in) financing activities
(268,961)
11,338,492
Net increase/(decrease) in cash and cash equivalents
(3,197,405)
8,560,644
Cash and cash equivalents at the beginning of the financial year
13,750,743
5,146,169
Effects of exchange rate changes on cash and cash equivalents
262,701
43,930
Cash and cash equivalents at the end of the financial year
10,816,039
13,750,743
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.
41
NYRADA INC (ASX:NYR)
Notes to the Consolidated Financial Statements
1. General information
The financial statements cover Nyrada Inc (the "company"). as a Consolidated Entity consisting of Nyrada Inc. and the
entities it controlled at the end of, or during, the year (the "Consolidated Entity"). The financial statements are presented
in Australian dollars, which is Nyrada Inc.'s functional and presentation currency.
Nyrada Inc is a company incorporated in the State of Delaware in the United States and registered in Australia as a foreign
company. As a foreign company registered in Australia, Nyrada Inc is subject to different reporting and regulatory regimes
than Australian public companies.
A description of the nature of the Consolidated Entity's operations and its principal activities are included in the Directors'
report, which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 29 August 2022.
2. Significant accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies
have been consistently applied to all the years presented, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The Consolidated Entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period, therefore there is no
impact to the financial statements..
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
Basis of preparation
These general purpose financial statements have been prepared in accordance with Australian Accounting Standards
and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as
appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting
Standards as issued by the International Accounting Standards Board ('IASB').
Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires
management to exercise its judgement in the process of applying the Consolidated Entity's accounting policies. The areas
involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the
financial statements, are disclosed in note 3.
Parent entity information
In accordance with the Corporations Act 2001, these financial statements present the results of the Consolidated Entity
only. Supplementary information about the parent entity is disclosed in note 13.
Principles of consolidation
The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Nyrada Inc. (‘Company'
or 'Parent entity') as at 30 June 2022 and the results of all subsidiaries for the year then ended. Nyrada Inc. and its
subsidiaries together are referred to in these financial statements as the 'Consolidated Entity'.
Subsidiaries are all those entities over which the Consolidated Entity has control. The Consolidated Entity controls an entity
when the Consolidated Entity is exposed to, or has rights to, variable returns from its involvement with the entity and has
the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated
from the date on which control is transferred to the Consolidated Entity. They are de-consolidated from the date that
control ceases.
Intercompany transactions, balances and unrealised gains on transactions between entities in the Consolidated Entity
are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the
asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the
policies adopted by the Consolidated Entity.
42
ANNUAL REPORT FY22
2. Significant accounting policies (cont’d)
The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership
interest, without the loss of control, is accounted for as an equity transaction, where the difference between the
consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly
in equity attributable to the parent.
Where the Consolidated Entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and
non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The
Consolidated Entity recognises the fair value of the consideration received and the fair value of any investment retained
together with any gain or loss in profit or loss.
Revenue recognition
The Consolidated Entity recognises revenue as follows:
Interest
Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the
amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest
rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset
to the net carrying amount of the financial asset.
Government Grants
In the financial year ending 30 June 2022 the Consolidated Entity has accounted for the current year accrued R&D Tax
Incentive. In the 2021FY the Consolidated Entity reported the 2020FY R&D Tax Incentive refund accrued and prior year
received.
Government research and development tax incentives
Government grants, including research and development incentives are recognised at fair value when there is reasonable
assurance that the grant will be received and all grant conditions will be met.
Income tax
The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the
applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable
to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when
the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted,
except for:
• When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability
in a transaction that is not a business combination and that, at the time of the transaction, affects neither the
accounting nor taxable profits; or
• When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures,
and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse
in the foreseeable future.
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that
future taxable amounts will be available to utilise those temporary differences and losses.
The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred
tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for
the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is
probable that there are future taxable profits available to recover the asset.
Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets
against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable
authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.
43
NYRADA INC (ASX:NYR)
2. Significant accounting policies (cont’d)
Current and non-current classification
Assets and liabilities are presented in the statement of financial position based on current and non-current classification.
An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the
Consolidated Entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised
within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged
or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.
A liability is classified as current when: it is either expected to be settled in the Consolidated Entity's normal operating
cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or
there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All
other liabilities are classified as non-current.
Cash and cash equivalents
Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly
liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash
and which are subject to an insignificant risk of changes in value.
Trade and other receivables
Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective
interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement
within 30 days.
The Consolidated Entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime
expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on
days overdue.
Other receivables are recognised at amortised cost, less any allowance for expected credit losses.
Investments and other financial assets
Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the
initial measurement, except for financial assets at fair value through profit or loss. Such assets are subsequently measured
at either amortised cost or fair value depending on their classification. Classification is determined based on both the
business model within which such assets are held and the contractual cash flow characteristics of the financial asset
unless an accounting mismatch is being avoided.
Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and the
Consolidated Entity has transferred substantially all the risks and rewards of ownership. When there is no reasonable
expectation of recovering part or all of a financial asset, its carrying value is written off.
Financial assets at fair value through profit or loss
Financial assets not measured at amortised cost or at fair value through other comprehensive income are classified as
financial assets at fair value through profit or loss. Typically, such financial assets will be either: (i) held for trading, where
they are acquired for the purpose of selling in the short-term with an intention of making a profit, or a derivative; or (ii)
designated as such upon initial recognition where permitted. Fair value movements are recognised in profit or loss.
Impairment of financial assets
The Consolidated Entity recognises a loss allowance for expected credit losses on financial assets which are either
measured at amortised cost or fair value through other comprehensive income. The measurement of the loss allowance
depends upon the Consolidated Entity's assessment at the end of each reporting period as to whether the financial
instrument's credit risk has increased significantly since initial recognition, based on reasonable and supportable
information that is available without undue cost or effort to obtain.
Where there has not been a significant increase in exposure to credit risk since initial recognition, a 12-month expected credit
loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a
default event that is possible within the next 12 months. Where a financial asset has become credit impaired or where it is
determined that credit risk has increased significantly, the loss allowance is based on the asset's lifetime expected credit
losses. The amount of expected credit loss recognised is measured on the basis of the probability weighted present value of
anticipated cash shortfalls over the life of the instrument discounted at the original effective interest rate.
For financial assets measured at fair value through other comprehensive income, the loss allowance is recognised within
other comprehensive income. In all other cases, the loss allowance is recognised in profit or loss.
44
ANNUAL REPORT FY22
2. Significant accounting policies (cont’d)
Property, plant and equipment
Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes
expenditure that is directly attributable to the acquisition of the items.
Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment
(excluding land) over their expected useful lives as follows:
Plant and equipment
3-7 years
Trade and other payables
These amounts represent liabilities for goods and services provided to the Consolidated Entity prior to the end of the
financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not
discounted. The amounts are unsecured and are usually paid within 30 days of recognition.
Research and development expenditure
Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is
probable that the project will be a success considering its commercial and technical feasibility; the Consolidated Entity is
able to use or sell the asset; the Consolidated Entity has sufficient resources and intent to complete the development; and
its costs can be measured reliably. Capitalised development costs are amortised on a straight-line basis over the period
of their expected benefit.
Finance costs
Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in
the period in which they are incurred.
Employee benefits
Short-term employee benefits
Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be
settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities
are settled.
Other long-term employee benefits
The liability for long service leave not expected to be settled within 12 months of the reporting date are measured at the
present value of expected future payments to be made in respect of services provided by employees up to the reporting
date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience
of employee departures and periods of service. Expected future payments are discounted using market yields at the
reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible,
the estimated future cash outflows.
Share-based payments
Equity-settled and cash-settled share-based compensation benefits are provided to employees.
Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for
the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount
of cash is determined by reference to the share price.
The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined
using either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the
option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the
expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that
do not determine whether the Consolidated Entity receives the services that entitle the employees to receive payment. No
account is taken of any other vesting conditions.
The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the
vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the
best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount
recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already
recognised in previous periods.
45
NYRADA INC (ASX:NYR)
2. Significant accounting policies (cont’d)
The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either
the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the
award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:
•
•
during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied
by the expired portion of the vesting period.
from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at
the reporting date.
All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid
to settle the liability.
The Consolidated Entity assesses non market performance conditions. As at 30 June 2022 the Consolidated Entity
assumes Key Management Personnel non-market performance conditions will be achieved.
If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made.
An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair
value of the share-based compensation benefit as at the date of modification.
If the non-vesting condition is within the control of the Consolidated Entity or employee, the failure to satisfy the condition
is treated as a cancellation. If the condition is not within the control of the Consolidated Entity or employee and is not
satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period,
unless the award is forfeited.
If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining
expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and
new award is treated as if they were a modification.
Fair value measurement
When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the
fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date; and assumes that the transaction will take place either: in the
principal market; or in the absence of a principal market, in the most advantageous market.
Fair value is measured using the assumptions that market participants would use when pricing the asset or liability,
assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its
highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are
available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of
unobservable inputs.
Issued capital
Ordinary shares are classified as equity.
Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax,
from the proceeds.
Goods and Services Tax ('GST') and other similar taxes
Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not
recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part
of the expense.
Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST
recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of
financial position.
Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities
which are recoverable from, or payable to the tax authority, are presented as operating cash flows.
Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.
46
ANNUAL REPORT FY22
3. Critical accounting judgements, estimates and assumptions
The preparation of the financial statements requires management to make judgements, estimates and assumptions that
affect the reported amounts in the financial statements. Management continually evaluates its judgements and
estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements,
estimates and assumptions on historical experience and on other various factors, including expectations of future events,
management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates
will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of
causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the
next financial year are discussed below.
Coronavirus (COVID-19) pandemic
Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may
have, on the Consolidated Entity based on known information. This consideration extends to the nature of the supply chain,
staffing and geographic regions in which the Consolidated Entity operates. Other than as addressed in specific notes,
there does not currently appear to be either any significant impact upon the financial statements or any significant
uncertainties with respect to events or conditions which may impact the Consolidated Entity unfavourably as at the
reporting date or subsequently as a result of the Coronavirus (COVID-19) pandemic.
Share-based payment transactions
The Consolidated Entity measures the cost of equity-settled transactions with employees by reference to the fair value of
the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or
Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The
accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the
carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.
Recovery of deferred tax assets
Deferred tax assets are recognised for deductible temporary differences only if the Consolidated Entity considers it is
probable that future taxable amounts will be available to utilise those temporary differences and losses.
Assessment of R&D expenditure not advancing to a stage of technical feasibility
Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is
probable that the project will be a success considering its commercial and technical feasibility; the Consolidated Entity is
able to use or sell the asset; the Consolidated Entity has sufficient resources and intent to complete the development; and
its costs can be measured reliably.
4. Operating segments
From the period beginning 1 July 2019 the Board considers that the Consolidated Entity has only operated in one Segment
being research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of
significant medical needs and it operates in one geographical area being Australasia. The financial information presented
in the statement of financial performance and statement of financial position represents the information for the
business segment.
47
NYRADA INC (ASX:NYR)
5. Other income
Interest received
Grant income
Other income
6. R&D grant revenue
2022
$
13,830
45,411
59,241
2022
$
2021
$
3,989
50,000
53,989
2021
$
R&D grant revenue
1,048,333
2,286,022
R&D grant revenue recorded in 2022 relates to the accrued FY2022 refund (2021: $2,286,022 recognised relating to the
FY2020 refund received of $976,372 and the accrued FY2021 refund of $1,309,650).
7. Trade, other receivables and prepayments
2022
$
2021
$
Current assets
R&D Tax Incentive Receivable
1,048,333
1,309,650
Prepayments
Other receivables
8. Trade and other payables
Current liabilities
Trade payables
Accrued expenses
Other payables
82,486
22,906
1,688
49,483
1,153,725
1,360,821
2022
$
65,420
295,027
22,508
2021
$
87,195
433,428
67,406
382,955
588,029
48
ANNUAL REPORT FY22
9. Issued capital
Ordinary shares - fully paid
156,008,700
156,008,700
25,320,332
25,320,332
2022
2021
Shares
Shares
2022
$
2021
$
Common Stock
At the beginning of reporting
period/year
Issue of Common Stock
Issue of Common Stock upon exercising
of options
Issuance of common stock - Advisors
Share based payments - exercise of
options
Less: Share placement costs
Less: Share based payments - Broker
options
Less: Share based payments -
reclassification in share capital
30 Jun 2022
30 Jun 2021
30 Jun 2022
30 Jun 2021
Shares
Shares
$
$
156,008,700
109,383,722
25,320,332
15,607,349
-
-
-
-
-
-
-
44,231,154
1,441,901
951,923
-
-
-
-
-
-
-
-
-
-
-
11,500,899
369,680
304,615
183,152
(782,537)
(1,214,494)
(648,332)
At the end of reporting period/year
156,008,700
156,008,700
25,320,332
25,320,332
The Company has CHESS Depositary Interests (CDIs) quoted on the Australian Securities Exchange (ASX) trading under
the ASX code NYR. Each CDI represents an interest in one share of Class A common stock of the Company (Share).
Legal title to the Shares underlying the CDIs is held by CHESS Depositary Nominees Pty Ltd (CDN), a wholly owned subsidiary
of the ASX. The Company’s securities are not quoted on any other exchange.
CDI Holders are entitled to participate in dividends and the proceeds on the winding up of the company in proportion to
the number of and amounts paid on the shares held.
CDI Holders may attend and vote at Nyrada’s general meetings. The Company must allow CDI Holders to attend any
meeting of Shareholders unless relevant U.S. law at the time of the meeting prevents CDI Holders from attending those
meetings.
Options on issue
There were no options issued in the current reporting period.
Performance Common Stock
The Company has issued the following Performance Common Stock in the Company (Performance Shares):
At the beginning of the reporting period
18,000,000
18,000,000
2022
No
2021
No
49
NYRADA INC (ASX:NYR)
9. Issued capital (continued)
The Performance Shares shall be convertible into 18,000,000 Shares upon the achievement of the milestones referred to
below on or before 25 November 2024. The fair value of each Performance Share at grant date is $0.08:
Holder
shares
Performance milestones
Performance
Noxopharm
Limited
Altnia
Holdings
Pty Ltd
6,000,300
The later to occur of:
•
•
the trading price for the Company’s CDIs achieving at least AU$0.40 for 5
consecutive trading days on the ASX; and
the Scientific Advisory Board to the Company determining that, based on
in-vivo data, the final lead neuroprotectant drug candidate is ready to
proceed to pre-clinical safety and toxicology studies.
6,000,300
The later to occur of:
•
•
the trading price for the Company’s CDIs achieving at least AU$0.40 for 5
consecutive trading days on the ASX; and
the Scientific Advisory Board to the Company determining that, based on
in-vivo data, the final lead peripheral neuropathic pain drug candidate is
ready to proceed to pre-clinical safety and toxicology studies.
5,999,400
The later to occur of:
• the trading price for the Company’s CDIs achieving at least AU$0.40 for 5
consecutive trading days on the ASX; and
• the Scientific Advisory Board to the Company determining that, based on
in-vivo data, the final lead PCSK9 inhibiter drug candidate is ready to
proceed to pre-clinical safety and toxicology studies.
Total
18,000,000
If the relevant performance milestones are not achieved on or before 25 November 2024, the Performance Shares held by
each holder will be automatically redeemed by the Company for the sum of AU$1.00.
Each Performance Share shall be convertible into one (1) fully paid and non-assessable Share upon the terms and
conditions set forth herein. The Company will at all times reserve and keep available, solely for the purpose of issue upon
conversion of the outstanding Performance Shares, such number of Shares as shall be issuable upon the conversion of all
such outstanding shares; provided, that nothing contained herein shall be construed to preclude the Company from
satisfying its obligations in respect of the conversion of the outstanding Performance Shares by delivery of Shares which
are held in the treasury of the Company.
The Company covenants that if any shares, required to be reserved for purposes of conversion hereunder, require
registration with or approval of any governmental authority under any federal or state law before such shares may be
issued upon conversion, the Company will use its best efforts to cause such shares to be duly registered or approved, as
the case may be. The Company will endeavour to list the shares required to be delivered upon conversion prior to such
delivery upon each national securities exchange, if any, upon which the outstanding shares are listed at the time of such
delivery. The Company covenants that all Shares which shall be issued upon conversion of the Performance shares will,
upon issue, be fully paid and non-assessable and not entitled to any pre-emptive rights.
Fifty Percent (50%) of the Nox Performance Common Stock will automatically convert into Shares upon 10 Business Days
after the First Milestone and the Second Nox Milestone are both satisfied, such that each such share of Nox Performance
Common Stock will convert into one Share.
Fifty Percent (50%) of the Nox Performance Common Stock will automatically convert into Shares upon 10 Business Days
after the First Milestone and the Third Nox Milestone are both satisfied, such that each such share of Nox Performance
Common Stock will convert into one Share.
The Altnia Performance Common Stock will automatically convert into Shares upon 10 Business Days after the First
Milestone and the Second Altnia Milestone are both satisfied, such that each such share of Altnia Performance Common
Stock will convert into one Share. Altnia is a related party of Ian Dixon.
Upon the occurrence of a Change of Control:
•
•
that number of Performance Shares that, after conversion, is no more than 10% of the issued and outstanding
capital stock of the Company (as at the date of the Change of Control) may by the Holder be converted into Shares;
the Company shall ensure a pro-rata allocation of shares of Shares issued under this paragraph to all Holders; and
• any Performance Shares that are not converted into Shares in accordance with this Section will continue to be held
by the Holder on the same terms and conditions.
50
ANNUAL REPORT FY22
9. Issued capital (continued)
Procedures for Conversion
The Company will issue the Holders with a new holding statement for the Shares within 2 Business Days following the
conversion of the Performance Shares into Shares.
Restrictions on Transfer
The Performance Shares shall be issued only to, and shall be held only by those persons designated by the Board. Any
purported sale, transfer, pledge or other disposition of any Performance Shares to any person, other than a successor to
such designated person by merger or reorganisation of the designated person, or a duly authorised agent acting for the
benefit of such designated person, shall be null and void and of no force and effect.
No Dividends or Distributions
Holders shall not be entitled to share in any dividends or other distributions of cash, property or shares of the Company,
whether in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or otherwise.
No Pre-emptive Rights
No Holder shall be entitled as of right to purchase or subscribe for any part of any unissued or treasury stock of the
Company, or of any additional stock of any class, to be issued by reason of any increase of the authorized capital stock
of the Company, or to be issued from any unissued or additionally authorized stock, or of bonds, certificates of
indebtedness, debentures or other securities convertible into stock of the Company, but any such unissued or treasury
stock, or any such additional authorized issue of new stock or securities convertible into stock, may be issued and disposed
of by the Board to such persons, firms, corporations or associations, and upon such terms as the Board may, in its
discretion, determine, without offering to the Holders then of record, on the same terms or any terms.
Reorganisation
If and for the period that the Company is admitted to the official list of ASX:
•
If there shall occur a reorganisation, recapitalisation, reclassification, consolidation or merger involving the
Company (Reorganisation), then the rights of the Holder (including the number of Shares into which a Performance
Share may be converted) will be changed to the extent necessary to comply with the listing rules of ASX applying
to a reorganisation of capital stock at the time of the Reorganisation.
• Any calculations or adjustments which are required to be made will be made by the Board and will, in the absence
of manifest error, be final and conclusive and binding on the Company and the Holder.
•
The Company must, within a reasonable period, give to the Holder notice of any change to the number of Shares
into which a Performance Share held by the Holder may be converted.
Redemption
If the Performance Shares have not been converted into Shares within five (5) years after the date of issue of the
Performance Shares, then the Performance Shares held by a Holder at that date will be automatically redeemed by the
Company for the sum of AUD1.00 within ten (10) Business Days of the expiration of that five (5) year period.
10. Reserves
2022
$
2021
$
Share-based payments reserve
5,693,864
4,726,913
Share-based payments reserve
The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their
remuneration, and other parties as part of their compensation for services.
11. Dividends
There were no dividends paid, recommended or declared during the current or previous financial year.
51
NYRADA INC (ASX:NYR)
12. Unrecognised carry-forward tax losses
The Company has income tax revenue losses of approximately $7,533,789 (2021: $5,708,177) for which no deferred tax asset
has been recognised.
13. Parent entity information
Set out below is the supplementary information about the parent entity.
Statement of profit or loss and other comprehensive income
2022
$
Parent
2021
$
Loss after income tax
(2,195,362)
(8,226,143)
Total comprehensive income
(2,195,362)
(8,226,143)
Statement of financial position
Total current assets
Total non-current assets
Total assets
Total current liabilities
Total liabilities
Equity
Issued capital
2022
$
Parent
2021
$
8,021,863
9,466,431
-
-
8,021,863
9,466,431
79,805
79,805
268,962
268,962
25,320,332
25,320,332
Share-based payments reserve
5,693,864
4,726,913
Accumulated losses
Total equity
(23,072,138)
(20,849,776)
7,942,058
9,197,469
Guarantees entered into by the parent entity in relation to the debts of its subsidiaries
The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2022 and 30 June 2021.
Contingent liabilities
The parent entity had no contingent liabilities as at 30 June 2022 and 30 June 2021.
Capital commitments - Property, plant and equipment
The parent entity had no capital commitments for property, plant and equipment as at 30 June 2022 and 30 June 2021.
Significant accounting policies
The accounting policies of the parent entity are consistent with those of the Consolidated Entity, as disclosed in note 2,
except for the following:
•
•
Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be
an indicator of an impairment of the investment.
52
14. Subsidiaries
Nyrada Pty Ltd
Norbio No.2 Pty Ltd
Cardio Therapeutics Pty Ltd
ANNUAL REPORT FY22
2022 ownership
2021 ownership
interest
interest
100%
100%
100%
100%
100%
100%
15. Events after reporting period
On 1 August 2022 the Company announced the appointment of Dr. Gisela Mautner as a Non-Executive Director to its Board
and retirement of Peter Marks.
No other matters or circumstances has arisen since 30 June 2022 that has significantly affected, or may significantly affect
the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future
financial years.
16. Cash flow information
Reconciliation of loss after income tax to net cash used in operating activities
2022
$
2021
$
Loss after income tax expense for the year
(3,959,661)
(3,539,253)
Adjustments for:
Depreciation & amortisation
Share-based payments
Change in operating assets and liabilities
Decrease/(increase) in trade and other receivables
Increase/(decrease) in trade and other payables
Increase/(decrease) in employee benefits
4,734
966,951
207,096
(197,978)
55,170
1,811
1,111,622
(281,976)
(98,620)
33,568
(2,923,688)
(2,772,848)
Reconciliation of Cash
Cash at the end of financial year as included in the statement of cash flows is reconciled to the related items in the
statement of financial position as follows:
Cheque account
USD account
Saving bonus
2022
$
421,940
2,450,841
7,943,258
2021
$
220,229
4,122,025
9,408,489
10,816,039
13,750,743
53
NYRADA INC (ASX:NYR)
17. Share-based payments
During the year the number of options and performance shares representing amounts in the share-based payments
reserve did not change (total of 49,500,000 options and 18,000,000 performance shares). The vesting charge taken to the
profit and loss in-respect of these options and shares for the year was $966,951. Details of the fair value assumptions
underpinning these share-based payment arrangements are disclosed in previous years' financial reports of
the Company.
The weighted average exercise price at the end of the financial year was $0.21 (2021: $0.21). The weighted average
remaining contractual life of options and performance shares outstanding at the end of the financial year was 1.75 years
(2021: 2.75 years).
18. Loss per share
Loss after income tax attributable to the owners of Nyrada Inc.
(3,959,661)
(3,539,253)
2022
$
2021
$
Weighted average number of ordinary shares used in
calculating basic earnings per share
Weighted average number of ordinary shares used in
calculating diluted earnings per share
Basic loss per share
Diluted loss per share
2022
2021
Number
Number
156,008,700
116,743,748
156,008,700
116,743,748
2022
$
(0.03)
(0.03)
2021
$
(0.03)
(0.03)
There are 28,900,000 of options which have vested and are considered to be dilutive. The options are not included as the
Consolidated Entity is loss-making, so incorporating in the impacts of contingent equity is anti-dilutive.
19. Key Management Personnel disclosures
Compensation
The aggregate compensation made to directors and other members of Key Management Personnel of the Consolidated
Entity is set out below:
Short-term employee benefits
Post-employment benefits
Share-based payments
2022
$
864,908
27,375
570,297
2021
$
691,632
24,441
966,096
1,462,580
1,682,169
54
ANNUAL REPORT FY22
20. Related party transactions
Key Management Personnel
Any person(s) having authority and responsibility for planning, directing and controlling the activities of the entity, directly or
indirectly, including any director (whether executive or otherwise) of that entity, are considered Key Management Personnel.
For details of disclosures relating to Key Management Personnel, including who is included within these disclosures, refer
to the remuneration report contained in the Directors’ report and note 19.
21. Commitments and contingencies
There are no significant commitments and contingencies at balance date in the current or prior reporting periods.
22. Financial instruments
Capital management
The Consolidated Entity manages its capital to ensure entities in the Consolidated Entity will be able to continue as going
concern while maximising the return to stakeholders through the optimisation of the debt and equity balance.
The Consolidated Entity's overall strategy remains unchanged from 2021.
The Company is not subject to any externally imposed capital requirements, except for Chapter 6 of the Corporations Act
2001 in relation to take over provisions and Chapter 7 of ASX listing rules on 15% placement capacity on new equity raising.
Given the nature of the business, the Consolidated Entity monitors capital on the basis of current business operations and
cash flow requirements.
Categories of financial instruments
Financial assets
Cash and cash equivalents
Trade and other receivables
Financial liabilities
Trade and other payables
2022
$
10,816,039
1,153,725
11,969,764
2021
$
13,750,743
1,360,821
15,111,564
382,955
588,029
The fair value of the above financial instruments approximates their carrying values.
Financial risk management objectives
In common with all other businesses, the Consolidated Entity is exposed to risks that arise from its use of financial
instruments. This note describes the consolidated entities objectives, policies and processes for managing those risks and
the methods used to measure them. Further quantitative information in respect of those risks is presented throughout
these financial statements.
There have been no substantive changes in the Consolidated Entity's exposure to financial instrument risks, its objectives,
policies and processes for managing those risks or the methods used to measure them from previous periods unless
otherwise stated in this note.
The Board has overall responsibility for the determination of the consolidated entities risk management objectives and policies
and, whilst retaining ultimate responsibility for them, it has delegated the authority for designing and operating processes that
ensure the effective implementation of the objectives and policies to the consolidated entities finance function.
The Consolidated Entity's risk management policies and objectives are therefore designed to minimise the potential
impacts of these risks on the Consolidated Entity where such impacts may be material. The Board receives monthly
financial reports through which it reviews the effectiveness of the processes put in place and the appropriateness of the
objectives and policies it sets. The overall objective of the Board is to set policies that seek to reduce risk as far as possible
without unduly affecting the Consolidated Entity's competitiveness and flexibility.
55
NYRADA INC (ASX:NYR)
22. Financial instruments (continued)
Foreign currency risk management
The Consolidated Entity undertakes transactions denominated in foreign currencies; consequently, exposures to
exchange rate fluctuations arise. At 30 June 2022, the Company has cash denominated in US dollars (US$1,689,791 (2021:
US$3,089,998)). The A$ equivalent at 30 June 2022 is $2,450,841 (2021: $4,122,025). A 5% movement in foreign exchange
rates would increase or decrease the Consolidated Entity’s loss before tax by approximately $122,956 (2021: $208,443).
Liquidity risk management
Ultimate responsibility for liquidity risk management rests with the Board of Directors, which has established an
appropriate liquidity risk management framework for the management of the consolidated entities short, medium and
long-term funding and liquidity management requirements. The Consolidated Entity manages liquidity by maintaining
adequate banking facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity
profiles of financial assets and liabilities.
Carrying
Less than 1
3-12
1 year to 5
contractual
Amount
month
1-3 months
months
years
cash flows
Total
2022
$
$
$
Trade and other
payables
382,955
250,142
132,813
$
-
$
-
$
382,955
23. Remuneration of auditors
Audit and review services
William Buck Audit (Vic) Pty Ltd
2022
$
2021
$
35,000
33,500
56
ANNUAL REPORT FY22
Directors’ Declaration
In the Directors' opinion:
•
•
•
•
the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards,
the Corporations Regulations 2001 and other mandatory professional reporting requirements;
the attached financial statements and notes comply with International Financial Reporting Standards as issued
by the International Accounting Standards Board as described in note 2 to the financial statements;
the attached financial statements and notes give a true and fair view of the Consolidated Entity's financial
position as at 30 June 2022 and of its performance for the financial year ended on that date; and
there are reasonable grounds to believe that the Consolidated Entity will be able to pay its debts as and when
they become due and payable.
The Directors have been given the declarations required by section 295A of the Corporations Act 2001.
Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.
On behalf of the Directors
___________________________
John Moore
Non-Executive Chairman
29 August 2022
57
NYRADA INC (ASX:NYR)
Shareholder Information
Corporate Governance Statement
The Company’s corporate governance statement is located at the Company’s website:
https://www.nyrada.com/site/ About-Us/corporate-governance
CHESS Depositary Interests
The Company has CHESS Depositary Interests (CDIs) quoted on the Australian Securities Exchange (ASX) trading under
the ASX code NYR. Each CDI represents an interest in one share of Class A common stock of the Company (Share). Legal
title to the Shares underlying the CDIs is held by CHESS Depositary Nominees Pty Ltd (CDN), a wholly owned subsidiary of
the ASX. The Company’s securities are not quoted on any other exchange.
All information provided below is current as at 17 August 2022 except as otherwise stated. To avoid double-counting, the
holding of Shares by CHESS Depositary Nominees Pty Limited (underpinning the CDIs on issue) have been disregarded in
the presentation of the information below, unless otherwise stated.
Distribution of CDIs
Analysis of number of equitable security holders by size of holding:
Holding Ranges
Holders
Total Units
% Share Capital
1 to 1,000
1,001 to 5,000
5,001 to 10,000
10,001 to 100,000
100,001 and over
Total
30
400
283
851
237
1,801
3,311
1,269,819
2,337,289
32,381,735
120,016,546
0.00%
0.81%
1.50%
20.76%
76.93%
156,008,700
100.00%
Unmarketable parcels
There are 243 shareholdings held with less than a marketable parcel, totalling 482,198 shares or 0.31% of the total CDIs.
Unlisted securities
•
•
•
•
•
•
18,000,000 Performance Common Stock, with terms and conditions outlined in the Prospectus (released to the
ASX on 14 January 2020)
8,000,000 Broker Options, with an exercise price of $0.20 and expiry date of 30 June 2024
33,500,000 ESOP Options, of which 31,500,000 with terms and conditions outlined in the Prospectus (released to
the ASX on 14 January 2020) and 2,000,000 were subsequent allotments
4,000,000 Broker Options, with an exercise price of $0.40 and expiry date of 29 June 2026
2,000,000 Broker Options, with an exercise price of $0.60 and expiry date of 29 June 2026
2,000,000 Broker Options, with an exercise price of $0.90 and expiry date of 29 June 2026
58
ANNUAL REPORT FY22
Distribution of Unlisted Securities (> 20% holding)
Performance
Common Stock
Broker
Options2
ESOP
Options
Holder
NOXOPHARM LIMITED
ALTNIA HOLDING PTY LTD (I DIXON FAMILY A/C)
GRAHAM KELLY
ANNA CARINA PTY LTD (ANNA CARINA FAMILY A/C)
MERSOUND PTY LIMITED
MR JODET DURAK
%
66.67%
33.33%
-
-
-
-
%
-
-
-
30.00%
30.00%
30.00%
%
-
-
53.73%
-
-
-
Note 1 – There are no holders that hold >20% for the following unlisted securities
•
•
8,000,000 Broker Options, with an exercise price of $0.20 and expiry date of 30 June 2024
4,000,000 Broker Options, with an exercise price of $0.40 and expiry date of 29 June 2026
Note 2 – Broker Options for the following unlisted securities, noting the option holders for each tranche of broker options are the same
•
•
2,000,000 Broker Options, with an exercise price of $0.60 and expiry date of 29 June 2026
2,000,000 Broker Options, with an exercise price of $0.90 and expiry date of 29 June 2026
Voting rights
CDI Holders may attend and vote at Nyrada’s general meetings. The Company must allow CDI Holders to attend any
meeting of Shareholders unless relevant U.S. law at the time of the meeting prevents CDI Holders from attending those
meetings.
In order to vote at such meetings, CDI Holders may:
•
•
•
instruct CDN, as the legal owner, to vote the Shares underlying their CDIs in a particular manner. A voting
instruction form will be sent to CDI Holders with the notice of meeting or proxy statement for the meeting and this
must be completed and returned to the Registry before the meeting;
inform Nyrada that they wish to nominate themselves or another person to be appointed as CDN’s proxy for the
purposes of attending and voting at the general meeting; or
convert their CDIs into a holding of Shares and vote these at the meeting. Afterwards, if the former CDI Holder
wishes to sell their investment on the ASX it would need to convert the Shares back to CDIs. In order to vote in
person, the conversion from CDIs to Shares must be completed before the record date for the meeting.
One of the above steps must be undertaken before CDI Holders can vote at Shareholder meetings.
CDI voting instruction forms and details of these alternatives will be included in each notice of meeting or proxy statement
sent to CDI Holders by Nyrada.
Required Statements
The Company advises that the Annual General Meeting (AGM) of the Company is scheduled for Monday 21 November
2022 at 10:00am (AEDT). The meeting will be held as a virtual meeting. Further details on the virtual meeting arrangements
will be confirmed closer to the AGM.
Further to Listing Rule 3.13.1, Listing Rule 14.3, nominations for election of directors at the AGM must be received not less than
35 Business Days before the meeting, being no later than Monday 3 October 2022.
On-Market buy-back
There is no current on-market buy-back.
59
NYRADA INC (ASX:NYR)
Twenty (20) largest shareholders of quoted equity securities
Position
Holder
NOXOPHARM LIMITED
Holding
% held
33,373,245
21.39%
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
ALTNIA HOLDING PTY LTD
9,921,725
6.36%
SUNSET CAPITAL MANAGEMENT PTY LTD
2,548,197
1.63%
COLIN HOUSELY & FREDA HOUSELY
1,863,725
1.19%
MR MANFRED ZIMMER & MRS BEATRICE ZIMMER
1,600,000
1.03%
KYRIACO BARBER PTY LTD
SYMPHONY CAPITAL HOLDINGS LLC
PROFESSOR GARY DAVID HOUSLEY
MR JOHN GARDNER
JOHN W KING NOMINEES PTY LTD
RHLC PTY LIMITED
CANARY CAPITAL PTY LTD
DIXSON TRUST PTY LIMITED
MR GRAHAM ARTHUR ROBINSON
1,430,077
0.92%
1,425,000
0.91%
1,411,411
0.90%
1,300,000
0.83%
1,242,483
0.80%
1,150,000
0.74%
1,134,615
0.73%
1,100,000
0.71%
1,082,888
0.69%
HIMSTEDT & CO PTY LTD
1,057,000
0.68%
HARLUND INVESTMENTS PTY LTD
1,010,000
0.65%
SENTINEL INVESTMENT MANAGEMENT PTY LTD
1,000,000
0.64%
DOSSMAN PTY LTD
959,625
0.62%
MR COLIN JAMES EASTERBROOK & MRS JANET ELIZABETH EASTERBROOK
950,000
0.61%
20
MR MICHAEL FRANCIS MCMAHON & MRS SUSAN LESLEY MCMAHON
899,616
0.58%
60
ANNUAL REPORT FY22
References
Pg 2
1. Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association
statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin
Lipidology. 2016
Pg 5
Pg 9
2. National Academies of Sciences, Engineering, and Medicine 2022. Traumatic Brain Injury: A
Roadmap for Accelerating Progress. Washington, DC: The National Academies Press.
https://doi.org/10.17226/25394.
3. National Academies of Sciences, Engineering, and Medicine 2022. Traumatic Brain Injury: A
Roadmap for Accelerating Progress. Washington, DC: The National Academies Press.
https://doi.org/10.17226/25394.
4. World Health Organization, Ageing and health factsheet, 4 October 2021, available online.
5. CDC, QuickStats: Prevalence of High Total Cholesterol Among Adults Aged ≥20 Years, by Age
Group and Sex — National Health and Nutrition Examination Survey, 2015–2018. MMWR Morb
Mortal Wkly Rep 2020;69:690 available online.
6. Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association
statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin
Lipidology. 2016.
7. Chen X, Lu M, He X, Ma L, Birnbaumer L, and Liao, Y. (2017). TRPC3/6/7 knockdown protects the
brain from cerebral ischemia injury via astrocyte apoptosis inhibition and effects on NF-small
ka, CyrillicB translocation. Mol. Neurobiol. 54, 7555–7566. doi: 10.1007/s12035-016-0227-2.
8. National Academies of Sciences, Engineering, and Medicine 2022. Traumatic Brain Injury: A
Roadmap for Accelerating Progress. Washington, DC: The National Academies Press.
https://doi.org/10.17226/25394.
9. National Academies of Sciences, Engineering, and Medicine 2022. Traumatic Brain Injury: A
Roadmap for Accelerating Progress. Washington, DC: The National Academies Press.
https://doi.org/10.17226/25394.
61
NYRADA INC (ASX:NYR)
[This page is intentionally left blank]
62
ANNUAL REPORT FY22
63
NYRADA INC (ASX:NYR)
www.nyrada.com
64